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ABSTRACT
MOLECULAR ANALYSIS OF SENESCENCE-ASSOCIATED PROTEIN 
PHOSPHATASES DUSP10 AND MTMR11
Suna Pelin Gülay
MSc. in Molecular Biology and Genetics
Supervisor: Assoc. Prof. Rengül Atalay
July 2009, 129 Pages
Liver cancer is the fifth most common cancer in the world. Until recently, tumor cells 
were thought to proliferate indefinitely. In a previous study, our group showed 
spontaneous induction of replicative senescence in p53- and p16INK4a-deficient 
HCC (hepatocellular carcinoma) cell clones. The gene expression profiling was later 
done for these different clones, in an attempt to find novel therapeutic targets in HCC. 
Since protein kinases are known to be very important in disease formation and 
carcinogenesis, their partners in signaling, protein phosphatases should also be 
important in these processes. Hence analysis and targeting of protein phosphatases 
genes with differential expression between immortal and senescent clones might
prove beneficial for HCC therapeutics. Among the phosphatase genes with 
differential expression patterns, we focused on two most upregulated genes in 
senescent clones with respect to immortal clones, DUSP10 and MTMR11. After 
gathering detailed information on these genes and their products by bioinformatics 
analysis, we confirmed the upregulation of the two genes in our senescent clones 
compared to our immortal clones by semi-quantitative RT-PCR. We then checked 
DUSP10 and MTMR11 expression in HCC and breast cancer cell lines to see if a 
differential expression of these genes are observed in different subtypes of these cell 
lines. Other experiments on MTMR11 focused on discovery of novel transcripts of 
this gene in HCC and breast cancer cell lines and checking the amounts of different 
transcripts in different subtypes of these cell lines, to form a bridge between 
MTMR11 transcript variants and carcinogenesis, however we did not observe 
differential expression. Two microarray studies comparing non-tumor and HCC 
tissues have listed MTMR11 as upregulated in HCC. Hence, upregulation of this gene 
in senescent clones may not be significant in hepatocarcinogenesis or replicative 
senescence, and further experiments should be performed. Considering DUSP10, we 
checked the subcellular localization of this protein in HCC cell lines by 
immunostaining, to see if the two subtypes (well-differentiated and poorly-
differentiated) of HCC cell lines differed in DUSP10 localization. We observed some 
cell lines having only nuclear or only cytoplasmic DUSP10, whereas most had both 
nuclear and cytoplasmic DUSP10. This lead the way for us to explore the factors that 
may be important in changing this protein’s localization, as this may be a type of 
regulation on this protein, and may change during carcinogenesis or upon induction of 
senescence. For this purpose, we checked to see if DUSP10 changed its localization in 
aging MRC-5 cell passages compared to young, proliferating ones and in premature 
senescence-induced cells compared to normal ones. Interestingly, it was found that 
upon replicative senescence induction, but not premature senescence, DUSP10 
localized more to the cell nucleus which indicated a connection between DUSP10 
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localization and replicative senescence. We also checked to see if DUSP10 changed 
its localization upon disruption of the MAPK pathways it participates in, by kinase 
inhibitor experiments. Interestingly, it was found that DUSP10 localized significantly 
more to the cell nucleus upon inhibition of JNK pathway but not p38 pathway, in 
well-differentiated subtype of HCC cell lines. DUSP10 localization did not change 
significantly in poorly-differentiated subtype of HCC cell lines. Although JNKs, 
which seem to regulate DUSP10 through its localization according to this study, act as 
oncogenes in HCC, the significance of the change in DUSP10 localization should be 
characterized further before stating that DUSP10 can be a putative tumor suppressor.
However, our other results indicate a relationship between DUSP10 localization and 
replicative senescence, which is promising because DUSP10 has emerged from our 
group’s microarray data as a replicative senescence-associated gene, and this 
connection should be analyzed further.
vÖZET
HÜCRE YAŞLANMASIYLA İLİNTİLİ DUSP10 VE MTMR11 FOSFATAZ 
GENLERİNİN MOLEKÜLER ANALİZİ
Suna Pelin Gülay
Moleküler Biyoloji ve Genetik Yüksek Lisansı
Tez Yöneticisi: Doç. Dr. Rengül Atalay
Temmuz 2009, 129 Sayfa
Karaciğer kanseri (hepatosellüler karsinom) dünya çapında en sık görülen beşinci 
kanser türüdür. Yakın bir zamana kadar, tümör hücrelerinin sonsuz bölünme 
kapasitesine sahip olduğu düşünülmekteydi. Grubumuzun önceki bir çalışmasında 
p53 ve p16INK4a proteinlerine sahip olmayan karaciğer kanseri hücre klonlarında 
kendiliğinden gelişen bir hücre yaşlanması olayı gösterildi. Elde edilen senesant ve 
ölümsüz klonlarda değişen gen ifadelerinin incelenmesi karaciğer kanseri için tedavi 
amaçlı yeni hedef gen ve proteinlerinin bulunmasini sağlayabilirdi. Biz de bu amaçla, 
yakın zamanda hücre içi sinyal iletiminde ve bunun zarar görmesi sonucunda oluşan 
hastalıklarda önemleri anlaşılmaya başlanmış olan fosfataz genlerine odaklandık ve 
çalışmamız için senesant klonlarda ifadesi ölümsüz klonlara göre en yüksek anlamlı 
artışı gösteren DUSP10 ve MTMR11 fosfataz genlerini seçtik. DUSP10, mitojenler 
tarafindan aktive edilen protein kinazlardan (MAPK) JNK ve p38’i deaktive eder. 
MTMR11 ise myotubularin fosfataz ailesindendir. Bu genlerin ve gen ürünlerinin 
detaylı biyoinformatik analizinden sonra, revers transkriptaz polimeraz zincir 
reaksiyonu (RT-PZR) ile senesant klonlarda ölümsüz klonlara göre ifadelerinin 
arttığını doğruladık. Değişik kökenli ve değişik farklılaşma oranlarına sahip karaciğer 
ve meme kanseri hücre hatlarında, RT-PZR ile DUSP10 ve MTMR11 genlerinin 
ifadesine baktik. Amacımız bu genleri kanser oluşumu ve hücre yaşlanmasıyla 
ilişiklendirmekti. MTMR11 konusundaki diğer deneyler, elimizdeki hücre hatlarında 
bu genin yeni ve değişik transkript formlarinin bulunmasina ve bu farklı 
transkriptlerin miktarının karaciğer ve meme kanseri hücre hattı alt-türlerinde 
değişiminin saptanmasına odaklandı. Bu konuda farklı alt-türleri farklı transkriptler 
ile ilişiklendiremedik. Başka iki mikrodizilim çalışmasında da MTMR11’in karaciğer 
kanserinde ifadesi artmış bir gen olarak gösterildiğini de göz önünde bulundurursak, 
grubumuzun mikrodizilim çalışmasında MTMR11’in ifadesinin senesant klonlarda 
artmış olması, bu gen ve ürününün kanserleşme veya senesansta fonksiyonel bir rolü 
olduğu anlamına gelmiyor olabilir. Bunu ileriki çalışmalar gösterecektir. DUSP10 için 
ise, yine değişik karaciğer kanseri hücre hattı alt-türlerinde (epitel veya mezenkim 
kökenli) bir fark yakalayabilmek için, bu proteinin hücre içindeki lokalizasyonunu 
immüno-boyama ile tespit ettik. Bu proteinin bazı hücre hatlarında sadece çekirdekte 
veya sadece sitoplazmada, çoğundaysa her iki yerde de olduğunu gözlemledik. Bir 
proteinin hücre içi lokalizasyonunun değişimi bir çeşit kontrol mekanizması 
olabileceği, bu da bu proteini kanserleşme veya hücre yaşlanmasıyla 
ilişkilendirebileceği için, hücre içi DUSP10 lokalizasyonunu değiştirebilecek 
faktörleri incelemeye yöneldik. Öncelikle telomere bağlı olan ve olmayan hücre 
yaşlanması tiplerinde bu proteinin lokalizasyonunun değişimine baktık. Bunun için 
genç MRC-5 fibroblast hücre hattı pasajları ile yaşlanmakta olan pasajları 
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karşılaştırdık. İlginç bir şekilde, DUSP10’un yaşlanmakta olan hücrelerde çekirdeğe 
lokalize olmaya başladığını gözlemledik. Değişik kimyasallarla erken (prematüre) 
hücre yaşlanmasına sebep olunduğunda ise DUSP10’un lokalizasyonunun 
değişmediğini gördük. Mikrodizileme çalışmasının yapıldığı klonlarda gözlemlenen 
hücre yaşlanmasının telomere bağlı olduğu düşünüldüğünde aldığımız sonuç 
DUSP10’un bu tip hücre yaşlanmasında kontrolünün değiştiğini göstermesi açısından 
umut vericiydi. Bunlara ilaveten, DUSP10 lokalizasyonunun p38 ve JNK sinyal 
yolaklarının kimyasal ilaçlarla engellenmesi üzerine değişip değişmediğine de baktık. 
İlginç bir şekilde, DUSP10’un JNK’nin inhibisyonu sonucunda anlamlı bir şekilde 
çekirdeğe lokalize olduğunu, bu sonucun p38’in inhibisyonu sonucunda ise 
oluşmadığını gördük. Ayrıca bu gözlemimizi epitel kökenli hepatosellüler karsinom 
hücre hatlarında yapabildik. Mezenkim kökenli hücre hatlarında ise DUSP10 
lokalizasyonunda bir değişiklik göremedik. Bu çalışmada DUSP10 lokalizasyonunu 
kontrol ettiği görülen JNK’ların hepatosellüler karsinomda onkoprotein olarak işlev 
gördükleri bilinmektedir. Yine de DUSP10’un tümör inhibisyonuyla veya telomere 
bağlı hücre yaşlanması ile olan ilişkisinin kesinleştirilmesi için bu proteinin hücre içi 
lokalizasyonundaki değişiminin öneminin başka deneyler aracılığıyla daha iyi 
anlaşılması gerekmektedir.
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1CHAPTER 1. INTRODUCTION
1.1 Protein phosphorylation and its regulation by kinases and phosphatases
Reversible post-translational modification is a very important process in regulating 
protein activity and thus crucial in cell signaling pathways. Many types of post-
translational modifications exist, including but not limited to phosphorylation, 
ubiquitination, acetylation, methylation, glycosylation and myristoylation. 
Historically, phosphorylation is the best studied of these modifications mostly due to 
the relative ease of detecting protein phosphorylation in vitro and in vivo (see Hunter 
T, 2007). Phosphoproteomic analysis has shown the extent of protein phosphorylation 
in mammalian cells and the temporal dynamics of this post-translational modification 
through mass spectrometry. A recent study has detected 6600 phosphorylation sites in 
2244 proteins of HeLa cell line and has further found that 14% of these sites are 
modulated at least 2-fold by epidermal growth factor (EGF) within 20 minutes (Olsen 
JV et al, 2006). These phosphoproteins include enzymes (specifically kinases), 
ubiquitin ligases, guanidine nucleotide exchange factors (GEFs), GTPase activating 
proteins (GAPs), transcription factors and other transcriptional regulators.
Phosphorylation is a well-characterized biochemical process in which a phosphate 
group is added through a phosphoester bond (O-phosphate) to the hydroxyl side chain 
of serine, threonine or tyrosine residues (Fig.1.1). The relative ratio of 
phosphorylation of these aminoacids in mammalian cells is about 1000:100:1 
respectively. Of lower frequency, N-phosphorylation of histidine residues is also 
observed (see Kowluru A, 2008). The low frequency of phosphorylation of a specific 
residue does not show its insignificance in signaling as tyrosine phosphorylation is a 
very important process regulating activities of various growth factor receptors (see 
Arena S et al, 2005).
Phosphates are negatively charged groups and their addition to a protein can cause a 
conformational change in that protein, regulating its binding affinities to other 
proteins and its substrates thus controlling its function in a signaling cascade. In 
addition to this allosteric regulation, the phosphate groups may exert steric effects on 
2proteins such as shielding their positive charges as seen in the case of histones (see 
Grant PA, 2001). In addition, when coupled to ubiquitination, protein phosphorylation 
may also be a step in the degradation of a protein. Hence, protein phosphorylation can 
be considered as a molecular switch, turning the protein activity on or off. 
Additionally, it is a rapid and reversible process, all of which must have contributed to 
its selection during evolution as a key mechanism for the control of cell homeostasis 
(see Hunter T, 2007; Arena S et al, 2005).
Fig.1.1: Frequently phosphorylated residues in humans: This image was retrieved from 
http://www.ionsource.com/Card/phos/phos.h1.gif on July 15th, 2009.
The key players in protein phosphorylation are kinases and phosphatases. Kinases are 
in charge of transferring phosphate groups from ATP molecules to their substrates, 
while phosphatases remove the phosphate groups from their substrates, reversing the 
action of kinases (see Arena S et al, 2005). 
1.1.1 Kinase gene family
Kinases represent 1.5-2.5% of all eukaryotic genes, thus confirming the prominent 
role of these enzymes in controlling key cellular functions. There are 478 classical 
kinases which can be characterized by the presence of a conserved catalytic domain. A 
kinome tree can be seen in www.sciencemag.org/cgi/data/298/5600/1912/DC2/1.
Kinases can be grouped into seven according to the sequence similarity between 
protein kinase domains: AGC (containing PKA, PKG, PKC families), CAMK 
(calcium/calmodulin dependent protein kinase), CK-1 (casein kinase 1), CMGC 
(containing CDK, MAPK, GSK3, CLK families), STE (homologs of yeast Sterile 7, 
Sterile 11, Sterile 20 kinases), TK (tyrosine kinase) and TKL (tyrosine kinase-like). 
There are also 40 atypical kinases including lipid kinases. Serine-threonine kinases 
comprise 67% of all kinases whereas tyrosine kinases comprise 17%. Tyrosine kinase-
like kinases and atypical kinases comprise 8% of all kinases each. Despite their 
3relatively low number, tyrosine kinases are involved in key signaling pathways, 
including the transduction of extracellular stimuli to the cell nucleus. Tyrosine kinases 
can further be divided into two subgroups: Receptor tyrosine kinases (RTKs) which 
include membrane-spanning receptors, such as EGFR, FGFR and c-MET, 
characterized by an extracellular ligand-binding domain and an intracellular kinase 
domain, and non-receptor tyrosine kinases (NRTKs) which include cytoplasmic 
proteins, such as SRC, ABL and Janus kinases, generally involved in the intracellular 
signaling cascades. There are also a number of dual-specificity kinases 
(phosphorylating both serine-threonine and tyrosine residues) including mitogen-
activated protein kinase kinases (MAPKKs, also known as MKKs) and cdc2-like 
kinases (CLKs), listed under different kinase groups (see Arena S et al, 2005).
1.1.2 Phosphatase gene family
Phosphatases generally counteract kinases in phosphorylation process by 
dephosphorylating proteins. They are newly acquiring a central importance in the 
control of proliferation, differentiation, cell adhesion and motility. There are 153 
protein phosphatases in the human genome, and they can be classified into three: 
Protein serine-threonine phosphatases (PSTPs), protein tyrosine phosphatases (PTPs) 
and dual specificity phosphatases (DSPs) which include both serine-threonine and 
tyrosine dephosphorylating phosphatases such as MAPK phosphatases (MKPs), and 
protein and lipid dephosphorylating phosphatases such as myotubularin related 
phosphatases (MTMRs). 54% of all phosphatases are PTPs, 27% are DSPs and 19% 
are PSTPs. In contrast with the kinome, in the phosphatome serine-threonine 
phosphatases are lower in number which is because of the relatively low number of 
PSTP catalytic subunits. However, PSTP function is mostly determined by regulatory 
subunits, exceeding 50 subunits for some PSTPs such as protein phosphatase 1 
(PPP1). Hence, the reactions PSTPs take part in are still numerous, including 
glycogen synthesis, muscle contractility, protein synthesis, stress response and 
regulation of circadian rhythm. PSTPs can be divided into three subgroups: PPPs 
(PPP1-7), PPMs (magnesium-dependent phosphatases, PPM1A-M and PPM2C) and 
FCP1 (dephosphorylation of RNA polymerase II carboxy-terminal-domain). Like 
TKs, PTPs can be divided into two subgroups: Receptor tyrosine phosphatases 
(RPTPs, further grouped according to protein structure and domains: R1-8, containing 
4phosphatases PTPRA-Z and PTPN5/STEP) and non-receptor tyrosine phosphatases 
(NRPTPs, further grouped according to protein structure and domains: NT1-9, 
containing phosphatases PTPN1-23 except PTPN5). RPTPs are generally implicated 
in processes that involve cell-cell and cell-matrix contact since they resemble cell-
adhesion molecules in their extracellular segment. NRPTPs are generally found to be 
associated with a variety of TKs and hence are important in regulation of signal 
transduction. Finally, DSPs can be divided into many families of various functions 
according to their conserved domains, the major ones being: DUSPs (DUSP1-
DUSP26 and DUPD1) (which bear yet another subfamily within: MAPK 
phosphatases/MKPs), Slingshots (SSH1-3), PRLs (PRL1-3), PTENs, MTMRs 
(MTM1 and MTMR1-13, this family includes pseudophosphatases with inactive 
catalytic sites that are important in regulation through binding) and CDC25 
(CDC25A-C). The phosphatase tree is shown in Fig.1.2. PTENs and MTMRs have 
both lipid and protein phosphatase activity, however their preferred substrates are 
lipids (see Arena S et al, 2005; Tonks NK, 2006; Alonso A et al, 2004).
Fig.1.2: Protein phosphatase tree.
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51.1.3 Deregulation of protein kinases and phosphatases in cancer and other 
diseases
Through phosphorylation, the cell regulates complex functions such as proliferation, 
differentiation, adhesion, metabolism and apoptosis (Fig.1.3). It is therefore not 
surprising that aberrant phosphorylation correlates strongly with the development of 
cancer and other complex diseases. Aberrant phosphorylation occurs through 
inactivation or hyperactivation of kinases and phosphatases.
Fig.1.3: Cell signaling circuitry: The proteins known to be functionally altered in cancer are 
highlighted in red. Kinases are circled in purple and phosphatases in pink (there is only one 
phosphatase in this scheme, PTEN, which is a dual specificity phosphatase acting mainly on PIP3). The 
abundance of protein kinases in signaling pathways resemble their importance for the cell (modified 
from Hanahan D, Weinberg RA, 2000).
Kinases are more studied than phosphatases in diseases and mostly are products of 
protooncogenes in case of cancer (Table 1.1). Kinase products of tumor suppressor 
genes also exist. For example, deletion of LKB1 (STK11) has been found to cause 
Peutz-Jeghers syndrome characterized by polyp formation in gastrointestinal tract. 
Downregulation of LATS1 (large tumor suppressor kinase 1) has been associated with 
an aggressive phenotype in breast cancers and molecular alterations of this gene have 
6been found in soft tissue sarcoma. Role of LATS1 in formation of soft tissue sarcomas 
has also been supported with knockout mice studies. MKK4 has been found to be 
mutated or deleted in a variety of human cancer cell lines, including pancreatic, testis, 
breast and colon cancer cell lines (Teng DH et al, 1997). Other well known examples 
of tumor suppressor kinases include CHEK2 and ATM which are important in DNA 
damage response, loss of function mutations of which cause Li-Fraumeni syndrome 
(characterized as a cancer predisposition syndrome) and ataxia telangiectasia 
(characterized by an increased sensitivity to ionizing radiation, this disease is 
neurodegenerative, it affects many parts of the body causing severe disability and 
susceptibility to cancer), respectively. Death-associated protein kinase 1 (DAPK1) is 
also a tumor suppressor candidate as its expression is lost in some human B-cell 
lymphoma, bladder, breast and renal carcinoma cell lines (Kissil JL et al, 1997). 
Interestingly, all these tumor suppressor and candidate kinases are either serine-
threonine or dual-specificity kinases. Many growth factor receptors (RTKs) are 
known to be encoded by protooncogenes or candidates (including EGFR, PDGFR, 
FGFR). Additionally, there are well known examples of protooncogenes among 
NRTK genes, including SRC and ABL. Other than cancer, kinases also take part in 
formation of a variety of diseases ranging from metabolic diseases such as diabetes to 
severe chronic immunodeficiencies and neurodevelopmental disorders (Table 1.1).
Gene Name Cancer Other Disease Effect in Cancer
LIMK1 Williams syndrome
INSR Leprechaunism, diabetes
PDGFRA
Atypical CML, gastrointestinal 
stromal tumors (GIST), 
pulmonary artery intimal 
sarcoma, glioblastoma, 
osteosarcoma, 
dermatofibrosarcoma 
protuberans 
Hypereosinophilic syndrome 
(HES), systemic mastocytosis 
(SM)
Oncogenic
PDGFRB
CMML, GIST, atypical CML, 
AML
Oncogenic
ABL CML, ALL, AML, GIST Oncogenic
ALK
Non-Hodgkins lymphoma, 
anaplastic large cell lymphoma 
(ALCL), inflammatory 
myofibroblastic tumor
Oncogenic
ABL2 (ARG) AML Oncogenic
RPS6KA3 Coffin-Lowry syndrome
ATM Ataxia-telangiectasia Tumor suppressive
CHEK2 Li-Fraumeni syndrome Tumor suppressive
AMPK
Wolff-Parkinson-White 
syndrome
EIF2AK3 Wolcott-Rallison syndrome
LKB1 Peutz-Jeghers syndrome Tumor suppressive
7MET
Papillary renal cancer,  HCC, 
HPRCC, HNSCC, gastric cancer, 
malignant melanoma, SCLC, 
musculoskeletal tumors, 
Oncogenic
FGFR1 Atypical CML
Craniosynostosis, Eosinophilia-
myalgia syndrome (EMS)
Oncogenic
FGFR3 Multiple myeloma, T lymphoma Oncogenic
FLT3 AML Oncogenic
CSF1R (c-FMS) AML Myelodysplastic syndrome Oncogenic
NTRK1 Papillary thyroid carcinoma Oncogenic
NTRK3
AML, congenital fibrosarcoma, 
mesoblastic nephroma, secretory 
breast carcinoma
Oncogenic
JAK3 X-linked SCID
ZAP70 Autosomal recessive SCID
RET
Familial medullary thyroid 
cancer, radiation-associated 
papillary thyroid carcinoma, 
multiple endocrine neoplasia 
types 2A and 2B, neuroblastoma
Hirschsprung disease Oncogenic
ROS1 Glioblastoma, astrocytoma Oncogenic
BTK
X-Linked 
agammaglobulinaemia
DMPK Myotonic muscular dystrophy
VEGFR-1 and -2
NSCLC and breast, prostate, 
renal, colorectal cancers (through 
overexpression of their ligands)
Oncogenic
KIT
AML, GIST, seminoma, SCLC, 
sarcomas
Systemic mastocytosis (SM), 
myelodysplastic syndrome
Oncogenic
PIK3CA
NSCLC, colorectal, brain and 
breast cancer
Oncogenic
CDKs
CLL, Non-Hodgkins’ lymphoma, 
breast and lung cancer
Oncogenic
SYK Myelodysplastic syndrome
RAF1 Kidney cancer, melanoma Oncogenic
P38 Rheumatoid arthritis
BRAF Melanoma, colorectal cancer Oncogenic
EGFR (ERBB1)
Glioblastoma, NSCLC, 
colorectal cancer, squamous cell 
carcinoma of head/neck 
(SCCHN), pancreatic cancer, 
ovarian cancer
Oncogenic
ERBB2 (HER-2) Breast, lung, ovarian cancer Oncogenic
ERBB3 Soft tissue clear-cell sarcoma Oncogenic
AKT2 Ovarian and pancreatic cancer Oncogenic
JAK2
Colorectal, lung, brain and breast 
cancer, AML, ALL, atypical 
CML
Polycythemia vera, 
myeloproliferative diseases
Oncogenic
PP2A* SV40 transformation Tumor suppressive
PRL-3* Colorectal cancer, HCC Oncogenic
PTPN11* AML, CML, ALL
Polycythemia vera, Noonan 
syndrome, LEOPARD 
syndrome
Oncogenic
PTPRG* Colorectal cancer Tumor suppressive
PTPN14* Colorectal cancer Tumor suppressive
PTPN13* Colorectal cancer Tumor suppressive
PTPRT* Colorectal, gastric, brain cancer Tumor suppressive
PTEN*
Glioma, prostate, breast, 
endometrial and colorectal 
cancer
Cowden syndrome, Bannayan-
Zonana syndrome, Lhermitte-
Duclos disease
Tumor suppressive
PPM1D* Breast and ovarian cancer Oncogenic
MTM1* X-linked myotubular myopathy
8PTPRE* Breast cancer Oncogenic
PTPN1* Insulin resistance, obesity
MTMR2* CMT syndrome type 4B
MTMR13* CMT syndrome type 4B
PTPN9* Autism
PTPRC* SCID, multiple sclerosis
PTPN6* Sezary syndrome
PTPRN1/2*
Markers for autoimmune 
diabetes
PTPN22*
SNP polymorphism in Type I 
diabetes
Table 1.1: Kinases and phosphatases that are implicated in various diseases: Various kinases and 
phosphatases, and the diseases they have a role in are shown. Also their effect in cancer (oncogenicity 
vs. tumor suppression) has been noted. (*) shows phosphatases (see Cohen P, 2001; Krause DS, Van 
Etten RA, 2005; Arena S et al, 2005; Janssens V et al, 2005; Gallego M, Virshup DM, 2005; Ventura J-
J, Nebreda AR, 2006).
Since phosphatases reverse the action of kinases, they can be considered as equally 
significant in disease formation, although their importance has been started to be 
discovered only recently. In the case of cancers, phosphatases are generally expected 
to be products of tumor suppressor genes. However just like there are tumor 
suppressor kinases, there are phosphatases encoded by protooncogenes and candidates 
(Table 1.1). For example, wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) has 
been shown to be amplified and overexpressed in multiple cancer types, including 
breast and ovarian carcinomas. This phosphatase is known to suppress important 
tumor suppressors such as p53, ATM, p16INK4A and ARF, hence its overexpression 
may mediate carcinogenesis through inactivation of these proteins (see Lu X et al, 
2008). Phosphatases of regenerating liver (PRLs), especially PRL-1 and PRL-3 have 
been associated with tumor progression, metastasis and angiogenesis. PRL-3 has been 
found to be amplified in colorectal cancer (see Arena S et al, 2005; Bessette DC et al, 
2008). PTPN11 (Shp2) has been found to be mutated in polycythemia vera (a 
myeloproliferative disorder characterized by overproduction of red blood cells), 
Noonan syndrome (a genetic disease affecting the whole body characterized by 
congenital heart malformation and neurological problems) and LEOPARD syndrome 
(“lentigines, electrocardiogram abnormalities, ocular hypertelorism, pulmonic 
stenosis, abnormalities of genitalia, retardation of growth, and deafness,” a 
multisystem disease). Additionally, somatic mutations of PTPN11 have been found in 
approximately 35% of patients with sporadic JMML (juvenile myelomonocytic 
leukemia) (see Chan G et al, 2008). Furthermore PTPN11 overexpression has been 
implicated in primary adult AML, CML and ALL (Xu R et al, 2005). PTPRE has been 
9implicated in aiding Neu (HER-2 or ERBB2) -induced mammary tumorigenesis (see 
Berman-Golan D et al, 2008). In addition to oncogenic phosphatases, there are also 
tumor suppressor and candidate phosphatases. One of the best known tumor 
suppressor phosphatase is PTEN, a dual specificity phosphatase that can act both on 
proteins and lipids, and its main target is PIP3. Deletion of PTEN has been observed in 
a variety of cancers including glioma, prostate, breast, endometrial and colorectal 
cancer. Another well known tumor suppressor phosphatase is PP2A, as it is known 
that small t antigen of SV40 tumor virus targets this phosphatase system to promote 
tumor formation. This is thought to occur by activation of PIP3 signaling pathway and 
stabilization of c-myc oncoprotein as both are targets of PP2A under normal 
physiological conditions (see Gallego M, Virshup DM, 2005). Just like kinases, 
phosphatases take part in a number of other diseases ranging from insulin resistance 
and obesity to myopathies and sensory neuropathies such as Charcot-Marie-Tooth 
(CMT) disease (Table 1.1).
Although there are many kinases and phosphatases whose role in cancer is well 
known as already mentioned, not everything is black and white for the functions of 
rest of these enzyme families in cancer development and progression. For example, 
there are controversial data on the role of MKPs in carcinogenesis. This is only 
normal because although ERK mainly shows oncogenic effect, the effects of JNK and 
p38 MAPKs changes according to the cancer type and stage. They act to suppress 
some cancers mainly through induction of apoptosis, whereas in some other cancers 
in which inflammation contributes to carcinogenesis, they act in favor of cancer 
development. Another complication especially important for JNK is that the duration 
and magnitude of signal mediated through it causes differential results such as 
proliferation versus apoptosis. Hence negative regulators of these two MAPK 
subtypes act either as oncoproteins or tumor suppressors depending on the cancer 
type, stage, the duration and magnitude of signaling (see Keyse SM, 2008; Krishna 
M, Narang H, 2008).
In an additional study, researchers have employed RNA interference to downregulate 
each known kinase and phosphatase in HeLa cell line, and have found that 73 kinases 
and 72 phosphatases are necessary for survival and growth and 12 other phosphatases 
function in sensitizing cells to apoptosis (MacKeigan JP et al, 2005), further 
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suggesting that kinases and phosphatases are vital for cells and that knowledge on 
these enzymes may lead to new treatment options for a large variety of diseases.
1.2 Hepatocellular carcinoma
Liver cancer is the fifth most common cancer in men and the eighth in women 
worldwide. It is also one of the leading causes of cancer-related deaths worldwide, 
ranking third in men and sixth in women (American Cancer Society, 2007). This high 
lethality rate is attributable in part to a resistance to existing anticancer agents, a lack 
of biomarkers that can detect surgically resectable incipient disease, and underlying 
liver disease that limits the use of chemotherapeutic drugs. Primary liver cancers 
include hepatocellular carcinoma, intrahepatic bile duct carcinoma 
(cholangiocarcinoma), hepatoblastoma, bile duct cystadenocarcinoma, 
haemangiosarcoma and epitheloid haemangioendothelioma, of which hepatocellular 
carcinoma is the most common (see Farazi PA, DePinho RA, 2006).
Hepatocarcinogenesis proceeds through a multi-step histological course. The 
discussed risk factors act to promote rounds of hepatocyte necrosis and regeneration 
that pave the way for development of a chronic liver disease. Liver injury and 
exposure to various cytokines, in a chronic liver disease condition, provoke stellate 
cell activation, which is associated with cellular proliferation and the robust synthesis 
of extracellular matrix components such as collagen, therefore contributing to liver 
fibrosis. Meanwhile the destruction-proliferation cycles also promote hepatocyte 
proliferative arrest due to telomere shortening (telomerase reactivation has also been 
associated with hepatocarcinogenesis, although the exact timing is not known). These 
changes lead to cirrhosis which is characterized by regenerative nodules surrounded 
by fibrous scar tissue (collagen). These nodules transform into hyperplastic nodules of 
regenerating hepatocytes which represent a potential first step towards HCC. 
Hyperproliferation of hepatocytes in these nodules causes accumulation of mutations 
and chromosome aberrations that leads to genomic instability, and results in pre-
malignant dysplastic nodules characterized by accumulation of lipids or glycogen 
inside the cell and nuclear crowding. Also abnormal liver architecture is seen at this 
stage. The dysplastic nodules can evolve into HCC due to high genomic instability 
and loss of p53. HCC has the capacity to invade the surrounding fibrous stroma and 
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vessels, and occasionally has metastatic potential. HCC can be further classified into 
well differentiated, moderately differentiated and poorly differentiated tumors, the last 
being the most malignant form of primary HCC. (see Goodman ZD, 2007; Farazi PA, 
DePinho RA, 2006).
1.2.1 Aetiologies of hepatocellular carcinoma
Fig.1.4: Risk factors and mechanisms of hepatocarcinogenesis (see Farazi PA, DePinho RA, 2006).
Hepatitis B virus (HBV) is the main causal factor of HCC globally, due to the fact that 
it is one of the most common diseases in the world, with an estimated 350 million 
chronically infected carriers worldwide. HBV is a single-stranded DNA virus of the 
hepadnavirus family that is integrated into the host genome. The integration of virus 
DNA may activate cellular proto-oncogenes or cause microdeletions that can target
cancer-relevant genes, although no consistent integration sites have been observed 
(see Lok AS, 2000). HBx protein has transcriptional activation activity that has been 
shown to alter the expression of growth-control genes, such as src tyrosine kinases, 
Ras, Raf, ERK and JNK (Tarn C et al, 2001). HBx protein has also been shown to 
bind and inactivate p53 by sequestration in vitro and to block p53 mediated apoptosis 
in vivo. ER stress and oxidative stress might also result due to viral-ER physical 
interactions (see Farazi PA, DePinho RA, 2006).
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Hepatitis C virus (HCV) is known to be the greatest risk factor for development of 
HCC, increasing the rate of HCC formation in patients with HCV approximately 17-
fold (Degos F et al, 2000). It is an RNA virus of the flaviviridae family. It has no 
reverse transcriptase activity and hence does not integrate itself into the host genome. 
Still, HCV shows a higher propensity to yield chronic infection which might relate to 
immune evasion by this virus, and that HCV shows a higher propensity to promote 
liver cirrhosis (see Farazi PA, DePinho RA, 2006). HCV core proteins have 
transcription regulatory functions on many different host genes, including the proto-
oncogene c-myc (Ray RB et al, 1995). HCV core proteins are also known to inhibit 
multiple activators of apoptosis, including Fas and tumor necrosis factor-α (TNF-α) 
(Marusawa H et al, 1999; Jin X et al, 2006). These effects of HCV core proteins may 
be exerted through the constitutive activation of ERK signaling cascade (Hayashi J et 
al, 2000). In addition to the core proteins, HCV nonstructural protein NS5A have been 
shown to interact with and inactivate p53 by sequestration to the perinuclear 
membrane (Majumder M et al, 2001). ER-stress and oxidative-stress-mediated 
mechanisms might also be possible for HCV-induced HCC (see Farazi PA, DePinho 
RA, 2006). Additionally HCV might be impairing immune system by interfering with 
T-cell activation (see Pachiadakis I et al, 2005). 
Chronic alcohol intake has been implicated in causing production of pro-
inflammatory cytokines through monocyte activation, in increasing intestinal 
permeability to bacteria/lipopolysaccharides, leading to Küpffer cell activation. 
Küpffer cells are specialized macrophages located in the liver and they release many 
chemokines and cytokines upon activation (including TNF-α, interleukin-1β, 
interleukin-6 and prostaglandin E) with adverse effects on hepatocyte survival. 
Chronic ethanol exposure causes hepatocytes to show increased sensitivity to the 
cytotoxic effects of TNF-α which may be responsible for chronic hepatocyte 
destruction-regeneration cycles leading to stellate cell activation, fibrosis, cirrhosis 
and ultimately HCC (see Farazi PA, DePinho RA, 2006; McKillop IH et al, 2006). 
Alcohol also damages the liver through oxidative stress mechanisms that result upon 
hepatic ethanol metabolism (see McKillop IH et al, 2006).
Aflatoxins are mycotoxins from Aspergillus flavus and Aspergillus parasiticus. 
Hepatic cytochrome p450 metabolizes aflatoxin (AFB1) and converts it to its highly 
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reactive exo-8,9-epoxide form. This epoxide reacts with guanine nucleotides in the 
hepatocyte DNA to form a number of adducts, which lead to heritable mutations that 
result in hepatocarcinogenesis (see McKillop IH et al, 2006). The main mechanism of 
AFB1 in hepatocarcinogenesis has been found to be GC→TA transversion at the third 
position of codon 249 of p53 gene (resulting in an Arg→Ser alteration in the protein) 
(Puisieux A et al, 1991). 
Other aetiological factors in HCC can be listed as follows:
 Non-alcoholic fatty liver disorders (NAFLD) and non-alcoholic steatohepatitis 
(see Farrell GC, Larter CZ, 2006).
 Type 2 diabetes and its associated hyperinsulinemia and hyper-IGF-1 
production (El-Serag HB et al, 2004).
 Certain metabolic disorders such as hereditary haemochromatosis, porphyria 
cutanea tarda, Wilson’s disease and primary biliary cirrhosis (see McKillop IH 
et al, 2006; Farazi PA, DePinho RA, 2006).
 Possibly use of oral contraceptives through their estrogen and progesterone 
components (see Maheshwari S et al, 2007; El-Serag HB, Rudolph KL, 2007).
1.3 Protein kinases and phosphatases implicated in hepatocarcinogenesis
Disruption of cell signaling is frequently seen in hepatocarcinogenesis. Mutations and 
other regulatory problems in p53 tumor suppressor, Wnt/β-Catenin pathway, growth 
factor receptors (including ErbB receptor family and c-MET) and their associated 
pathways, pRb tumor suppressor, Ras proteins and associated pathways, Janus kinases 
/ signal transducers and activators of transcription (JAK/STAT) pathway are observed.
Deregulation of protein phosphorylation in important signaling pathways is very 
important in initiation and progression of HCC. For example, in a recent study, PRL-3 
has been found to be significantly upregulated in HCC tumor tissues compared to the 
paired noncancerous liver tissues. The mRNA level of PRL-3 in tissues was also 
correlated with serum α-fetoprotein level, vascular invasion and metastasis in this 
study. Furthermore, a significant correlation between PRL-3 mRNA expression and 
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MMP-2, MMP-9 and E-cadherin has been found (Zhao WB et al, 2008). Another 
example is the tyrosine kinase p60c-src (SRC), which is overactivated in hepatoma 
cells and this is thought to account for the desensitization of liver tumor cells to 
TRAIL and CD95. SRC works with EGFR in desensitizing cells to apoptosis (De Toni 
EN et al, 2007). Another recent example may be DUSP1 (MKP-1). The expression of 
this MAPK phosphatase, a negative regulator of ERK, is dysregulated in liver tumors 
with poor prognosis. This is suggested to be through increased ubiquitination of 
DUSP1 by S-phase kinase-associated protein 2 (SKP2)/CDC28 protein kinase 1b 
(CKS1) ubiquitin ligase complex which leads to increased proteasomal degradation of 
DUSP1 (Calvisi DF et al, 2008). A final example comes from a very recent study on 
Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) which has been 
found to be overexpressed in about 54% of the 41 HCC samples and this 
overexpression has correlated with a more aggressive phenotype. Further experiments 
have also associated ROCK2 with increased invasiveness in HCC, which is in 
accordance with the fact that ROCKs normally regulate actin cytoskeleton and cell 
motility (Wong CC et al, 2009).
In addition to these specific and novel examples, there are a number of important 
signaling pathways known to be deregulated in HCC, in which kinases and 
phosphatases play major roles (Fig.1.5).
1.3.1 Growth factor receptor tyrosine kinases
ErbB family of receptor tyrosine kinases consists of ERBB1 (EGFR), ERBB2 
(HER2/neu), ERBB3 and ERBB4. EGFR has been found to be overexpressed in 4-
70% of HCC cases, HER2 in 0-30%, ERBB3 in 84% and ERBB4 in 61% (see 
Breuhahn K et al, 2006; Höpfner M et al, 2008; Farazi PA, DePinho RA, 2006).
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Fig.1.5: Major growth factor receptor signaling pathways important in HCC: Predominantly 
dysregulated components of signaling pathways are highlighted in dark gray. Seldom regulated 
components (eg. Smad 2/3), molecules not expressed by tumor cells (eg. HGF), and distinct protein 
family members dysregulated in HCC (eg. FZD-7) are highlighted in light gray (see Breuhahn K et al, 
2006).
Considering IGF signaling, expression of IGF-2R has been found to be reduced in 
63% of human HCC. Loss of heterozygosity at the igf-2r locus has also been observed 
in HCC and its premalignant lesions coupled to inactivating mutations of the second 
allele in 25% of the cases. Furthermore, several missense mutations are reported in 
HCC which target the extracellular domain of IGF-2R (see Breuhahn K et al, 2006; 
Höpfner M et al, 2008).
Mesenchymal-epithelial transition factor (MET) is a proto-oncogene encoding for a 
membrane receptor tyrosine kinase, of which hepatocyte growth factor (HGF) is the 
only known ligand. Overexpression of the MET receptor has been observed in 20-
48% of tumor samples. This induction in HCC cells may be attributed to genomic 
alterations (7q gains have been observed in 16.8% of HCCs), tumor hypoxia or HGF-
dependent transcriptional activation of MET (Breuhahn K et al, 2006; Höpfner M et 
al, 2008; Farazi PA, DePinho RA, 2006).
There are different data on the expression of TGFβ receptors, which are serine-
threonine kinases, in HCC. There are studies that have not detected a change in 
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expression levels of the receptors. In another study, upregulation of TGF-βRI levels 
has been detected in 60% of the cases. In yet another one, downregulation of TGF-
βRI levels has been detected in 80% of the cases. In some studies, including this latter 
study, downregulation of TGF-βRII levels has been detected in 37-70% of the cases. 
Overall, most studies document a reduction of the receptors in up to 70% of HCCs. 
(Breuhahn K et al, 2006).
1.3.2 Kinases and phosphatases of PI3K/PTEN/AKT/mTOR pathway
A major activation of this pathway can be either due to higher activity of receptor 
tyrosine kinases or to the reduced expression of PTEN, a negative regulator of the 
pathway. 10q loss is a genomic alteration that occurs in 17-27% of HCC cases, and 
this region also contains the PTEN gene. Furthermore, somatic missense mutations, 
frame shifts, splice site mutations and loss of promoter activity of PTEN have also 
been observed in HCC tissues and cell lines (Kawamura N et al, 1999; Ma DZ et al, 
2005; Fujiwara Y et al, 2000). Downstream of this pathway, mTOR, a serine-
threonine kinase implicated in the regulation of translation, is overexpressed in %50 
of HCC cases (n=314), as found in a recent broad study. Additionally, chromosomal 
gains in RICTOR were observed in 25% of patients (Villanueva A et al, 2008).
1.3.3 Mitogen-activated protein kinase (MAPK) pathways
The mitogen-activated protein kinase (MAPK) family consist of five subgroups, 
including the extracellular signal-regulated kinase homologs 1 and 2 (ERK1/2), big 
MAPK-1 (BMK-1/ERK5), c-Jun N-terminal kinase homologs 1, 2 and 3 (JNK1/2/3), 
stress-activated protein kinase 2 (SAPK-2) homologs α, β, and δ (p38α/β/δ), and 
ERK6 (p38γ). These kinases are activated through dual phosphorylation of T and Y 
residues located in their activation loop by their corresponding MAPK kinases 
(MKKs). MAPKs are implicated in diverse cellular processes such as cell growth and 
proliferation, differentiation, adhesion, apoptosis and stress response (see Pimienta G, 
Pascual J, 2007). Major MAPK pathways and their components are shown in Fig.1.6. 
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Fig.1.6: Mitogen-activated protein kinase pathways (see Zhang Y, Dong C, 2005).
Extracellular signal-regulated kinases (ERKs) or classical MAP kinases are widely 
expressed and are involved in functions including the regulation of cell proliferation 
and differentiation. Many different stimuli, including growth factors, cytokines, virus 
infection, ligands for heterotrimeric G protein-coupled receptors, transforming agents, 
and carcinogens, activate the ERK pathway. Main isoforms are ERK1 and ERK2 
(Krishna M and Narang H, 2008).
c-Jun N-terminal kinases (JNKs), originally identified as kinases that 
phosphosphorylate c-Jun on Ser63 and Ser73 within its transcriptional activation 
domain, are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat 
shock, and osmotic shock. They are involved in cell differentiation, proliferation and 
apoptosis. Main isoforms are JNK1 and JNK2 which are ubiquitiously expressed, and 
JNK3 which is only found in brain, heart and testes (Krishna M and Narang H, 2008).
Similar to JNK pathway, p38 MAP kinases are activated by a variety of cellular 
stresses including osmotic shock, heat shock, inflammatory cytokines, 
lipopolysaccharides (LPS), ultraviolet light and growth factors. They are involved in 
cell differentiation, apoptosis and Ras-induced senescence. Main isoforms are p38α, 
p38β, p38γ (also known as ERK6) and p38δ (Krishna M and Narang H, 2008).
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Other MAPKs are: ERK5, found recently, is activated both by growth factors and 
stress stimuli, and participates in regulation of cell proliferation, and, atypical MAPKs 
ERK3/4 and ERK7/8 which are cytoplasmic proteins and possess a C-terminal 
extension. Atypical MAPKs are also recently found and not much is known on them 
(Krishna M and Narang H, 2008).
Proteins of HBV, HCV and hepatitis E virus target and modulate multiple steps along 
MAPK pathway. In one study, it has been shown that HCV E2 protein, one of the two 
envelope glycoproteins of hepatitis C virus, activates the MAPK pathway in human 
hepatoma Huh-7 cells and promotes cell proliferation (Zhao LJ et al, 2005). 
Furthermore, increased levels of ERK have been observed in HCC and are known to 
correlate with tumor progression (Tsuboi Y et al, 2004). In another study, expression 
of Spred protein (Sprouty-related protein with Ena/vasodilator-stimulated 
phosphoprotein homology-1 domain), an inhibitor of the Ras/Raf-1/ERK pathway has 
been found to be deregulated in human HCC. Also in this study, ectopic 
overexpression of Spred has been observed to cause inhibition of ERK activation both 
in vivo and in vitro, resulting in reduced cancer cell proliferation and low secretion of 
MMP2 and MMP-9 (Yoshida T et al, 2006).
1.4 Cellular senescence and liver cirrhosis
Liver cirrhosis is the greatest clinical risk factor in hepatocarcinogenesis regardless of 
the aetiology underneath (HBV, HCV, aflatoxin or alcohol). In fact when compared to 
other cancers, HCC is characterized by an underlying cirrhosis condition, and 45-90% 
of all HCCs worldwide occur in the setting of liver cirrhosis. Cirrhosis has life-
threatening complications other than HCC, ascites (fluid retention in the abdominal 
cavity) being the most common one, leading to an increased risk of infection and a 
poor long-term outcome (see Goodman ZD, 2007). 
As already mentioned, liver cirrhosis is characterized by abnormal nodules of 
regenerating hepatocytes surrounded by fibrous scar tissue. Telomere shortening and 
senescence have been shown as the general markers of human liver cirrhosis, also 
correlating with progression of fibrosis in cirrhosis (Wiemann SU et al, 2002).
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Cellular senescence was initially defined as the loss of proliferative capacity of cells 
in culture typically after cultures have been passaged 50 or more times (Sherwood SW 
et al, 1988; Hayflick L, 1965). Cellular senescence, the state of stable cell cycle arrest, 
can be provoked by a variety of stimuli, such as telomere shortening, DNA damage, 
activation of certain oncogenes and oxidative stress (Fig.1.7). Senescence is 
associated with a number of gross cellular changes including cell-cycle arrest (see 
Collado M et al, 2005; Herbig U and Sedivy JM, 2006), increase in cell size and size 
heterogeneity, and increase in the frequency of cells with chromosomal aberrations, 
including polyploidy (Sherwood SW et al, 1988). Senescent cells display SABG 
(senescence-associated β-galactosidase) activity at pH 6.0 and this activity can be 
used as a marker to identify senescent cells. Other characteristic features of senescent 
cells include presence of p16INK4a, senescence-associated DNA-damage foci and 
senescence-associated heterochromatin foci (see Ozturk M et al, 2008). Cellular 
senescence acts as a barrier to cancer, preventing damaged cells from undergoing 
aberrant proliferation (see Chen JH et al, 2007, Campisi J, 2005), although it probably 
also has deleterious effects on organisms such as tissue aging (see Ozturk M et al, 
2008). Two well-established tumor suppressor proteins, pRb and p53, have been 
shown to play key roles in cellular senescence (Fig.1.8) (see Ben-Porath I and 
Weinberg RA, 2004).
Fig.1.7: Stimuli that cause cells to undergo senescence (see Chen JH, Hales CN, Ozanne SE, 2007).
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Fig.1.8: Molecular mechanisms of senescence (see Funayama R, Ishikawa F, 2007).
1.4.1 Replicative senescence and telomere shortening
Telomeres progressively shorten with age in somatic cells in culture and in vivo 
because DNA replication results in the loss of sequences at the 5' ends of double-
stranded DNA. Whereas somatic cells do not express the enzyme telomerase which 
adds repeated telomere sequences to chromosome ends, telomerase activity is 
detected in immortalized and cancer cells in vitro and in primary tumor tissues. This 
represents an important difference between normal cells and cancer cells, suggesting 
that telomere shortening causes cellular senescence (see Oshimura M and Barrett JC, 
1997). This form of senescence is called as replicative or telomere-dependent 
senescence. There is accumulating evidence that when only a few telomeres are 
shortened, they form end-associations, resulting in a DNA damage response which 
leads to replicative senescence (see Shay JW and Wright WE, 2004). This DNA 
damage signal leads to the activation of cell cycle checkpoint pathways involving 
p53, p16INK4a, and/or retinoblastoma (pRb) proteins (see Campisi J, 2005; Dimri 
GP, 2005). Inactivation of p53 and p16INK4a genes (see Shay JW and Bacchetti S, 
1997) and reactivation of hTERT gene expression (see Sherr CJ and McCormick F, 
2002) cause cells to gain replicative immortality (see Ozturk M et al, 2008).
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1.4.2 Premature (stress-induced) senescence
Replicative senescence is not the only form of senescence, as telomere-independent 
senescence mechanisms are also known, namely oncogene-induced senescence and 
oxidative stress-induced senescence (see Ozturk M et al, 2008). Telomere-
independent senescence is also known as premature senescence since it occurs in a 
short time after oncogenic activation or stress caused by reactive oxygen species 
(ROS), if the elements of the senescence or DNA damage pathways are intact. This is 
in contrast to telomere-dependent senescence which occurs roughly after 50 
population doublings in normal cells (see Funayama R, Ishikawa F, 2007). 
Additionally, hTERT expression does not prevent premature senescence (Gorbunova 
V et al, 2002).
Activated oncogenes such as Ras, Raf, Mos, Mek, Myc and Cyclin E are known to 
cause senescence. Loss of PTEN tumor suppressor gene also leads to senescence. 
Like replicative senescence, oncogene-induced senescence is mainly a DNA damage 
response, having ATM/ATR, CHK1/2, p53 and pRb as key players (see Ozturk M et 
al, 2008). Other mechanisms also contribute to the formation of this senescence type. 
p38 MAPK is known to play an important role in Ras-induced senescence. One of its 
targets, high mobility group (HMG)-box transcription factor 1 (HBP1) cooperates 
with pRb to mediate senescence whereas another target, p38-regulated/activated 
protein kinase (PRAK) phosphorylates p53 (see Funayama R, Ishikawa F, 2007).
Oxidative stress-induced senescence is caused by the reactive oxygen species (ROS), 
for which mitochondria are the main source. ROS have also been identified as critical 
mediators of replicative and oncogene-induced senescence, as these forms of 
senescence are accelerated in cells under oxidative stress (see Ozturk M et al, 2008). 
Although the exact mechanism of ROS-induced senescence is not known, studies 
have shown that p38 MAPK pathway might be important in mediating it, since 
inactivation of p38 delays the onset of various forms of cellular senescence, including 
the three that have been mentioned (see Funayama R, Ishikawa F, 2007). Additionally, 
ROS have been found to induce senescence in hematopoietic stem cells by activating 
p38 MAPK (see Ozturk M et al, 2008). However, the p38 targets important in 
mediating ROS-induced senescence are currently not known.
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1.5 Reprogramming of immortal cell lines for replicative senescence
Previously, Ozturk N and colleagues discovered spontaneous replicative senescence 
reprogramming in cultured cancer cell lines while working with empty vector-
transfected clones. This study hinted at a possible novel therapeutical approach 
against HCC by reversal of immortality in cancerous cells (Ozturk N et al, 2006).
1.5.1 Induction of spontaneous replicative senescence in stable clones derived 
from parental HCC cell lines
In the work of Ozturk N et al, analysis of clones from established HCC cell lines 
revealed that some empty vector transfected Huh7-derived clones showed phenotypes 
similar to cellular senescence. Two sets of clones were established according to their 
potential to undergo replicative senescence: C1/C3 clones (pcDNA 3.1 transfected) 
and G11/G12 clones (pEGFP-N2 transfected). C3 clones (C3L) went through only 80 
population doublings (PD), had very high senescence-associated-β-galactosidase 
(SABG) staining and very low BrdU staining, associated with very low rates of 
proliferation. On the other hand, C1 clones went through more than 150 population 
doublings and had very low SABG staining. Interestingly, parental Huh7 cells are 
composed of a heterogeneous population of cells on the basis of SABG staining, 
normally displaying about 20% staining. Early passage C3 clones (C3E; PD 57) also 
showed heterogeneous SABG staining and a normal phenotype. Similar results were 
obtained with G11/G12-Early/G12-Late clones. Hence this work showed that 
replicative immortality could be reversed and that cancer cells could generate 
senescent progeny spontaneously (Ozturk N et al, 2006).
1.5.2 Mechanism of spontaneous replicative senescence in stable clones derived 
from parental HCC cell lines
In an attempt to uncover the mechanism of spontaneous replicative senescence 
generated in these Huh7-derived stable clones, Ozturk N et al checked hTERT activity 
and telomere lengths in these cells. They found that the immortal C1 clones displayed 
hTERT activity and maintained their telomere length, whereas the senescent C3 
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clones displayed no detectable hTERT activity and had shortened telomeres. The 
researchers further analyzed the expression of known regulators of hTERT expression 
in the clones and found that a perfect reverse correlation was present between 
expression of hTERT and SIP1 (Zinc finger E-box binding homeobox 2; ZEB2) 
genes. This gene encodes a transcriptional repressor that interacts with Smad proteins 
of TGF-β signaling pathway and with CtBP co-repressor. Bypass of senescence arrest 
was observed after shRNA-mediated inactivation of SIP1 expression in C3 clones, 
further indicating SIP1 protein as a key regulator in this senescence mechanism 
(Ozturk N et al, 2006).
1.6 Gene expression changes between senescent and immortal Huh7 clones
1.6.1 Gene expression profiling of senescent and immortal Huh7 clones
Affymetrix gene expression profiling of Huh7-derived clones was performed to 
analyze the differences between immortal, senescent and revertant (C3-Early, G12-
Early) clones by our group (Ozturk M et al, unpublished results). Three copies of each 
cell clone were grown in a 175cm2 flask and RNA was extracted separately from each 
using Promega SV RNA Isolation Kit. Hence, no RNA pooling was done and the data 
were processed in triplicates. The samples were treated extensively with DNAse and 
the qualities of the obtained RNA samples were assessed using Agilent 2100 
Bioanalyzer and Agilent RNA 6000 Nano LapChip kit. RNA integrity was about 
100%, indicating no significant RNA degradation. cDNAs and eventually cRNAs 
were synthesized from the RNA samples by employing One Cycle cDNA Synthesis 
Kit from Affymetrix. 5μg of cRNA from each clone was hybridized to Affymetrix 
HGU133Plus2 Chips for 16 hours, adding up to 18 chips in total. The signals were 
detected according to the manufacturer’s protocol.
1.6.2 Analysis of genes differentially expressed between senescent and immortal 
clones 
The signals received from the chips were automatically saved as .CEL files by 
Affymetrix Scanner. These files were accessed and processed by the statistical 
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computing and graphics software, “R,” which converts signal intensities obtained 
from chips into numeric expression values of genes. Background correction and 
normalization of expression data by “RMA” algorithm were performed using the open 
source bioinformatics software, “Bioconductor” on “R” software environment. The 
data was then subjected to t-test analysis (two-tailed, unpaired, unequal variance) 
where the p-value limit was set to 0.05. Hierarchical clustering of genes was 
performed by GenePattern software. Finally, significant gene lists were obtained 
which contained the names of the genes differentially expressed between revertant, 
senescent and immortal clones.
Affymetrix HGU133Plus2 chip used in this microarray analysis contained 54675 
probes representing 47000 gene transcripts and variants corresponding to 
approximately 39000 human genes. The final Senescent vs. Immortal significant gene 
list contained 3073 genes represented by 3872 probes, the Revertant vs. Immortal 
significant gene list contained 2149 genes represented by 2552 probes and the 
Senescent vs. Revertant significant gene list contained 2023 genes represented by 
2388 probes. In total, there were 8812 probes representing 7245 genes with 
significantly differential expression (Ozturk M et al, unpublished data).
1.6.3 Identification of DUSP10 and MTMR11 as senescence-associated genes
Given the importance of protein phosphatases in diseases and cancer (including 
HCC), generating a significant phosphatase gene list by comparison of significant 
gene lists with all known phosphatase genes were of great interest for further studies. 
Since the primary aim in analyzing differentially expressed genes between the Huh7-
derived clones was to find therapeutically relevant novel genes important in 
“reversal” of immortality, the “Revertant” vs. Immortal gene list was of greatest 
importance. Other significant gene lists included genes also important in induction of 
senescence. Hence novel phosphatase genes in the Revertant vs. Immortal gene list 
were important the most, for our work. We initially aimed at finding phosphatase 
genes upregulated in immortal clones hinting at their possible oncogenicity in HCC. 
However, due to the fact that most upregulated genes were well-known and 
extensively studied, we turned to phosphatase genes downregulated in immortal 
clones compared to revertant and senescent ones demonstrating their possible tumor 
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suppressive activity in HCC. The significant phosphatase gene lists are shown in 
Table 1.2.
DUSP10 emerged as the most upregulated phosphatase gene in revertant clones 
compared to immortal ones with a fold change of 2.5 (1.3 fold in log2). Although this 
gene encodes a protein phosphatase that has been characterized in 1999 and has been 
studied thoroughly in immunology, it has not yet been studied in HCC. It is known to 
inactivate p38 and JNK MAPKs by dephosphorylation. Given the importance of 
MAPKs in hepatocarcinogenesis and the importance of p38 in mediating oxidative 
stress response and oncogene-induced senescence, DUSP10 (MKP-5) was of interest 
for our work. MTMR11 emerged as the most upregulated novel phosphatase gene in 
senescent clones compared to immortal ones with a fold change of 3.0 (1.6 fold in 
log2). This pseudophosphatase belongs to the myotubularin family of phosphatases 
and pseudophosphatases. Catalytically inactive phosphatases in this family are 
generally known to bind and regulate the active phosphatases. Upon these results, we 
chose DUSP10 and MTMR11 as our primary and secondary targets, respectively.
SENESCENT vs 
IMMORTAL
REVERTANT vs 
IMMORTAL
SENESCENT vs 
REVERTANT
Phosphatase
Fold 
Change
Phosphatase
Fold 
Change
Phosphatase
Fold 
Change
CDC25C -1.3 PTEN -0.9 CDC25A -1.233
PTEN -1.1 PPM1A -0.7 SSH1 -0.9
RNGTT -0.8 PPP1CB -0.7 CDC25B -0.8
PPP3CB -0.7 PTPN2 -0.7 CDC25C -0.65
PTPN2 -0.7 TPTE -0.6 PPP4C -0.6
DUSP14 -0.4 CDC25C -0.5 PTP4A2 -0.6
PPP2CA -0.4 MTMR12 -0.4 PTPN1 -0.4
PTPMT1 0.2 DUSP1 0.3 PHPT1 -0.3
DUSP1 0.5 CTDSP2 0.4 SBF1 -0.3
SSH3 0.5 DUSP4 0.4 PPTC7 -0.2
PTPRE 0.6 PPP2CA 0.4 CDC14B 0.2
DUSP4 0.7 PTPLB 0.4 DUSP4 0.2
DUSP16 0.95 PTPRF 0.4 DUSP1 0.3
PTPN2 1.1 DUSP7 0.6 PTPRK 0.5
CDC14B 1.2 DUSP16 0.8 TPTE 0.6
DUSP10 1.4 CDC25A 0.9 PTPRM 0.7
MTMR11 1.6 MTMR11 1.1 PPM1B 0.8
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CDC14B 1.15
DUSP10 1.3
Table 1.2: Differentially expressed phosphatases in significant lists: Fold changes are expressed in 
log2 base in this table. The protein phosphatases that were the foci of this study are shown in bold. The 
fold changes are in log2 base. This table was generated by Sevgi Bağışlar.
1.6.4 Cellular activities of DUSP10
Although it has been discovered in 1999 (Tanoue T et al, 1999; Theodosiou A et al, 
1999), not much is known on DUSP10 and studies concentrate on its roles in prostate 
cancer and in immunology.
Vitamin D is implicated in prevention of prostate cancer. A cDNA microarray study 
has been done in an effort to understand the basis of antitumor effects of Vitamin D in 
prostate cancer. In this study it has been found that 1,25-dihydroxyvitamin-D3 
(1,25D) form of Vitamin D causes an early, significant upregulation of DUSP10 
(Peehl DM et al, 2004). Further experiments have shown that upon 1,25D treatment in 
early prostate cancer (primary prostatic adenocarcinoma), DUSP10 is upregulated due 
to the presence of putative vitamin D response elements in its promoter. Upon 
upregulation, it dephosphorylates and inactivates p38 MAPK which normally causes 
production of proinflammatory cytokines such as interleukin-6 (IL-6). Since prostatic 
inflammation and IL-6 overexpression are key factors in formation of prostate cancer, 
DUSP10 acts as a tumor suppressor in early prostate cancer when overexpressed 
(Nonn L et al, 2006). Additional experiments have shown that curcumin, resveratrol 
and [6]-gingerol also upregulate DUSP10 in normal prostate cells (Nonn L et al, 
2007).
DUSP10 has been studied mainly in immunology and it has been found to regulate 
production of inflammatory cytokines and antigen presentation, showing its 
importance in both innate and adaptive immunity. In macrophages, TLR ligands 
induce DUSP10 expression which inhibits JNK activity and thereby constrains the 
production of cytokines and may reduce costimulation of T cells. In T cells, DUSP10 
is constitutively expressed and inhibits early JNK activation after TCR ligation. 
Increased JNK activity in the absence of DUSP10 results in reduced proliferation and 
increased AP-1-dependent production of T cell cytokines since AP-1 transcription 
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factor complexes are targets of JNK (see Lang R et al, 2006).
DUSP10 knockout mice are reported to only have immunological and haemotological 
phenotypes. These include increased number of activated T cells and enhanced APC 
priming in response to lipopolysaccharides (LPS) activation, decreased T cell 
proliferation in response to antigen, increased interferon-gamma, tumor necrosis 
factor, IL-2, IL-4 and IL-6 secretion, and decreased susceptibility to experimental 
autoimmune encephalomyelitis (EAE). These mice have also shown a fatal response 
to secondary viral challenge (Zhang Y et al, 2004).
1.6.5 Cellular activities of MTMR11
The only article on MTMR11 in NCBI Pubmed reports a common duplicated DNA 
sequence at 1q21.2 (includes MTMR11 gene according to Ensembl database) in acute 
lymphoblastic leukemia and Burkitt lymphoma (La Starza R et al, 2007), indicating a 
possible role of MTMR11 in these types of cancers.
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CHAPTER 2. OBJECTIVES AND RATIONALE
Hepatocellular carcinoma is among the most lethal and prevalent cancers in the 
human population. Despite its significance, there are only limited therapeutic options 
against it (Farazi PA, DePinho RA, 2006). Therefore, it is of ultimate importance to 
discover new approaches that could open up the way to novel therapeutic 
applications. The finding of Öztürk N et al that immortal cancer cells can be 
reprogrammed into replicative-senescent progeny that have lost tumorigenic potential 
is crucial in this aspect (Öztürk N et al, 2006).
Following the work of Öztürk N et al, gene expression profiling was performed on 
immortal and senescent clones since the differences between the expression profiles 
of these two types of clones could point out genes that are important in the reversion 
of the immortal phenotype of cancer cells. Further analysis of these genes may be 
important for new therapeutical approaches aiming to stop proliferation of cancer 
cells, or at least slow down tumor progression. After gene expression profiling, a set 
of genes were identified as differentially expressed between immortal and senescent 
clones. Of this set of significant genes, we were interested in protein phosphatase 
genes. Regulation of protein phosphorylation cascades is known to be disrupted in 
cancer and other diseases. Partnered to protein kinases, protein phosphatases are 
crucial players in protein phosphorylation which acts like a molecular switch 
mechanism turning target protein activities on and off. This renders protein 
phosphatases important in disease formation and carcinogenesis. In this study, we 
decided to focus on two novel protein phosphatases DUSP10 and MTMR11, which 
are significantly upregulated in senescent clones compared to immortal ones. 
Although information on these genes was limited and their tumor suppressive 
potentials were not known well, chromosomal aberrations targeting the chromosome 
arm they reside in (1q) in HCC bestowed an importance on them (mentioned in the 
Results chapter). We aimed the analysis of these two genes and their products to 
reveal their connection to hepatocarcinogenesis and replicative senescence, mainly by 
RT-PCR analysis to identify new potential transcript variants (MTMR11) in HCC cell 
lines, and by subcellular localization experiments to find out regulatory mechanisms 
related to replicative senescence (DUSP10). We expected to find significant difference 
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between the amounts of different transcripts of MTMR11 gene in subtypes of HCC 
cell lines (isolated from well-differentiated tumors vs. poorly-differentiated tumors) 
and breast cancer cell lines (originating from basal, luminal and mesenchymal 
tissues), leading to a possible explanation that different transcript variants of this gene 
is important in hepatocarcinogenesis or formation of breast cancer. For DUSP10, we 
expected to find a difference in subcellular localization between young and aging 
normal cells, indicating an importance of DUSP10 in replicative senescence, and 
between the mentioned subtypes of HCC cell lines, indicating a possible importance 
of DUSP10 in hepatocarcinogenesis. The results are shown and discussed in the 
following chapters.
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CHAPTER 3. MATERIALS AND METHODS
3.1 MATERIALS
3.1.1 Reagents
All laboratory chemicals were analytical grade from Sigma (St. Louis, MO, USA), 
Farmitalia Carlo Erba (Milano, Italy) and Merck (Schucdarf, Germany) with the 
following exceptions: Ethanol used for sterilization purposes was from Delta Kim 
Sanayi ve Ticaret A.S (Turkey). Commercial Bradford reagent, haematoxylin and 
nuclear fast red counterstains were also from Sigma. Kinase inhibitors JNK inhibitor 
V (AS601245) and Ro-31-8220 were obtained from Calbiochem. X-Gal was from 
Fermentas.
3.1.2 Enzymes and nucleic acids
Restriction endonucleases and T4 DNA ligase used for gene cloning were purchased 
from MBI Fermentas GmbH (Germany). Recombinant Taq DNA Polymerase and Pfu 
DNA Polymerase used for  polymerase chain reaction (PCR) were also purchased 
from the same company. DNA molecular weight standard and ultrapure 
deoxyribonucleotides were again from MBI Fermentas GmbH. pEGFP-N2 (Clontech, 
Palo Alto, CA, USA), pcDNA3.1/myc-His B (Invitrogen, Carlsbad, CA, USA) and 
pGEMT-Easy (Promega, Madison, WI, USA) were commercially obtained.
3.1.3 Oligonucleotides
The oligonucleotides used in PCR were synthesized by İONTEK (Istanbul, Turkey). 
The sequencing reactions for verifications of DNA sequences were also conducted by 
this company.
3.1.4 Electrophoresis, photography and spectrophotometer
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical 
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Company Ltd. (St. Louis, MO, USA). Horizontal electrophoresis apparatuses were 
from Stratagene (Heidelberg, Germany) and E-C Apparatus Corporation (Florida, 
USA). The power supply Power-PAC300 and Power-PAC200 was from Bio Rad 
Laboratories (CA, USA). The Molecular Analyst software used in agarose gel profile 
visualizing was from BioRad Laboratories (CA, USA). Spectrophotometer used for 
protein concentration measurements was from Beckman. For DNA and RNA 
concentration measurements, NanoDrop from Thermo Scientific was employed.
3.1.5 Tissue culture reagents and cell lines
Dulbecco’s modified Eagle’s medium (DMEM), Rosswell Park Memorial Institute 
(RPMI) medium 1640, fetal calf serum, L-glutamine, penicillin/streptomycin solution, 
trypsin and Geneticin (G418 sulfate) were obtained from GIBCO (Invitrogen, 
Carlsbad, CA, USA). Tissue culture flasks, petri dishes, cell plates were purchased 
from Corning Life Sciences Incorporated (USA).
3.1.6 Antibodies and chemiluminescence
The antibodies used in immunoblotting and immunohistochemistry were obtained 
from different sources, and their working dilutions are given in Table 3.1. ECL 
Western Blotting detection kit was purchased from Amersham Pharmacia Biotech Ltd. 
(Buckinghamshire, UK).
Working dilutionAntibody
Western 
Blot
Immunostaining
Source
DUSP10 (goat polyclonal) 1:200
1:50 (IF), 1:100 
(immunoperoxidase)
Abcam
Tubulin (mouse monoclonal) 1:1000 - Calbiochem
Calnexin (mouse 
monoclonal)
- No dilution Home-made (AF18)
B-actin (rabbit polyclonal) - 1:60 – 1:100 Santa Cruz Biotechnology
p-JNK (rabbit polyclonal) 1:100 - Cell Signaling Technologies
JNK (rabbit polyclonal) 1:300 - Cell Signaling Technologies
p-p38 (rabbit polyclonal) 1:100 - Cell Signaling Technologies
p38 (rabbit polyclonal) 1:300 - Cell Signaling Technologies
p-c-Jun (mouse monoclonal) 1:80 - Santa Cruz
c-Jun (rabbit polyclonal) 1:150 - Santa Cruz Biotechnology
Anti-goat-HRP 1:6000 1:1000 – 1:1500 Sigma
Anti-mouse-HRP 1:5000 - Sigma
Anti-rabbit-HRP 1:5000 - Sigma
32
Anti-goat Alexa Fluor 568 - 1:200 – 1:300 Invitrogen
Anti-mouse Alexa Fluor 488 - 1:400 Invitrogen
Anti-rabbit Alexa Fluor 488 - 1:200 Invitrogen
Table 3.1: Antibody dilution table.
3.2 SOLUTIONS AND MEDIA
3.2.1 General Solutions
50X Tris-acetic acid-EDTA (TAE): 2 M Tris-acetate, 50 mM EDTA pH 8.5. Diluted to 
1X for working solution.
Ethidium bromide: 10 mg/ml in water (stock solution), 30 ng/ml (working solution).
6x Loading dye solutions: 10mM Tris.HCl (pH 7.6), 0.03% bromophenol blue or 
0.03% xylene cyanol, 60% glycerol, 60mM EDTA (0.5M pH 8.0).
3.2.2 Microbiological media, reagents and antibiotics
Luria-Bertani medium (LB) Per liter: 10 g Bacto-tryptone, 5 g Bacto-yeast extract, 10 
g NaCl. For LB agar plates, add 15 g/L Bacto-agar.
Ampicillin: 100 mg/ml solution in double-distilled water, sterilized by filtration and 
stored at -20°C (stock solution). Workingsolution was 100 μg/ml.
Kanamycin: 300 mg/ml solution in double-distilled water sterilized by filtration and 
stored at -20°C (stock solution). Working solution was 30 μg/ml.
0.1 M IPTG: 1.41 g IPTG in 50 ml double-distilled water, sterilized by filtration and 
stored at -20C.
SOB medium: Per liter: 20 g tryptone (2%), 5 g yeastextract (0.5%), 0.584 g NaCl 
(10 mM), 0.186 g KCl (2.5 mM), 2.465 g MgSO4 and 2.03 g MgCl2 (10 mM) are put, 
autoclaved to sterilize, stored at room temperature.
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Transformation Buffer (TB): 10 mM PIPES, 15 mM CaCl2, 250 mM KCl are added, 
pH adjusted to 6.7 with KOH, 55 mM MnCl2 is added only after pH adjustment. Filter 
sterilized and stored at 4ºC.
Glycerol stock solution: 50% glycerol was mixed with 50% bacterial culture and 
stored at  -80ºC.
3.2.3 Tissue culture solutions
DMEM / RPMI working medium: 10% FBS, 1% penicillin/streptomycin, 1% Non-
Essential Amino Acid were added and stored at 4ºC.
10X Phosphate-buffered saline (PBS) Per liter: 80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH 7.4, diluted to 1X and autoclaved before use.
3.2.4 SDS (Sodium Deodecyl Sulfate)-PAGE (Polyacrylamide Gel 
Electrophoresis) solutions
30% Acrylamide mix (1:29) Per 100 ml: 29 g acrylamide, 1 g bisacrylamide in 
double-distilled water, filtered, degassed, and stored at 4°C (stock solution).
5X SDS gel-loading buffer: 3.8 ml double-distilled water, 1 ml of 0.5 M Tris-HCl, 0.8 
ml glycerol, 1.6 ml of 10% SDS, 0.4 ml of 0.05% bromophenol-blue. Before use, β-
mercaptoethanol was added to 5% to reach 1% when mixed with samples.
10X SDS-electrophoresis running buffer Per liter: 30.3 g Tris base, 144.0 g Glycine, 
10.0 g SDS. Diluted to 1X for working solution. Stored up to 1 month at 4°C.
10% Ammonium persulfate (APS): 0.1 g/ml solution in double distilled water 
(prepared freshly).
1.5 M Tris-HCl, pH 8.8 54.45 g: Tris base (18.15 g/100 ml) ~150 ml distilled water 
Adjust to pH 8.8 with 1 N HCl. Completed to 300 ml with distilled water and stored 
at 4°C.
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1 M Tris-HCl, pH 6.8 12.14 g: Tris base ~ 60 ml distilled water. Adjust to pH 6.8 with 
1 N HCl. Completed to 100 ml with distilled water and store at 4° C.
3.2.5 Immunoblotting solutions
1X Towbin wet transfer buffer with 10% Methanol Per liter: 3.03 g Tris-base, 14.4 g 
Glycine, 100 ml methanol, completed to 1 liter with double distilled water. pH is not 
adjusted.
10X Tris-buffer saline (TBS) Per liter: 100 mM Tris-base, 1.5 M NaCl, pH 7, in 
double distilled water.
TBS-Tween (TBS-T): 0.2 % Tween-20 solution in TBS (prepared freshly).
Blocking solution 5% (w/v): Non-fat milk, 0.2 % Tween-20 in TBS (prepared 
freshly).
3.2.6 Immunofluorescence and immunoperoxidase solutions
DAPI (4', 6-diamidino-2-phenylindole): 0.1-1 μg/ml (working solution in distilled 
water).
Immunofluorescence blocking solution: 5% BSA (bovine serum albumin) in 1X PBS.
Immunoperoxidase blocking solution: 10% FBS (fetal bovine serum) in 1X PBS.
3.2.7 SABG assay solutions
SABG buffer: Final concentrations of  40mM citric acid/sodium phosphate buffer (pH 
6.0), 5mM potassium ferrocyanide, 5mM potassium ferricyanide, 150mM NaCl, 2mM 
MgCl2, 1mg/ml X-Gal.
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3.3 METHODS
3.3.1 General Methods
3.3.1.1 Preparation of competent cells
3.3.1.1.1. Supercompetent E. Coli preparation
This method is based on a report by Inoue et al. 1990 (Inoue H et al, Gene, 1990). An 
overnight 10-20 ml E. coli DH5α culture was used to inoculate autoclaved SOB 
medium to an OD600 of 0.2. Bacteria were grown at 20ºC to an OD600 of 0.5-0.6 with 
vigorous shaking at 200 rpm and cooled down on ice for 10 minutes. Cells were 
transferred to 50 ml falcon tubes and centrifuged at 2500xg for 10 minutes (Hettich 
Rottina 420R, fixed-angle rotor, pre-cooled to 4ºC). The pellet was resuspended in 
ice-cold transformation buffer (1/3 of initial culture volume) by gently swirling and 
kept on ice for 10 minutes. The suspension was then centrifuged at 2500xg for 10 
minutes. The pellet was gently resuspended in ice-cold transformation buffer (1/12.5 
of initial culture volume) containing 7% DMSO and incubated on ice for 10 minutes.
Bacteria were put into 1.5-ml eppendorf tubes as 150μl aliquots. Tubes were 
immersed in liquid nitrogen to freeze rapidly and stored at –80ºC. Supercompetent 
bacteria were transformed by heat-shock method as described in 3.3.1.2.1.
3.3.1.1.2 Electrocompetent E. Coli preparation
An overnight 10-20 ml E. coli DH5α culture was used to inoculate autoclaved SOB 
medium to an OD600 of 0.2. Bacteria were grown at 20ºC to an OD600 of 0.5-0.6 with 
vigorous shaking at 200 rpm and cooled down on ice for 10 minutes. Cells were 
transferred to 50 ml falcon tubes and centrifuged at 2500xg for 10 minutes (Hettich 
Rottina 420R, fixed-angle rotor, pre-cooled to 4ºC). The pellet was resuspended in 
ice-cold autoclaved ddH2O (1/1.25 of initial culture volume) by gently swirling and 
kept on ice for 10 minutes. The suspension was then centrifuged at 2500xg for 10 
minutes. The pellet was gently resuspended in ice-cold 10% glycerol (1/12.5 of initial 
culture volume) and kept on ice for 10 minutes. At this stage, contents of different 
folcon tubes were joined. Cells were pelleted at 2500xg for 10 minutes and 
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resuspended in ice-cold 10% glycerol (1/500 of initial culture volume). The OD600 of 
bacteria at this stage was approximately 200-250. Bacteria were put into 1.5-ml 
eppendorf tubes as 50μl aliquots. Tubes were immersed in liquid nitrogen to freeze 
rapidly and stored at -80ºC. Electrocompetent bacteria were transformed by 
electroporation method as described in 3.3.1.2.2.
3.3.1.2 Transformation of E .coli
Transformation of plasmid DNA into E. coli was achieved by using heat-shock 
method and electroporation. 
3.3.1.2.1 Transformation by heat-shock method
Competent cells from -80ºC stock were thawed on ice. Bacteria were transfered into 
transformation tubes. 100-200 ng of ligation product or empty plasmid was added 
onto supercompetent cells. Then cells were incubated on ice for 30 minutes. After 
heat-shock for 45 seconds at 42ºC, the tubes were put on ice and 800 μl LB was 
added. Following incubation for 1 hour at 37ºC with vigorous shaking, cells with 
ligation products were pelleted for 1 min at highest speed in a bench microfuge 
(Heraeus Instruments Biofuge Pico), about 850μl of supernatant was discarded and 
pellet was resuspended in the remaining supernatant. Cells were plated out on LB-
agar with selective agent(s). 50μl of cells with empty plasmid were plated out without 
concentrating the pellet.
3.3.1.2.2 Electroporation of bacteria
Electrocompetent cells from –80ºC stock were thawed on ice. 100-200ng of ligation 
product or empty plasmid was put along wall of 0.2cm electroporator cuvette. 
Bacteria were pipetted onto the DNA drop. The cuvette was flicked to settle the 
mixture to the bottom of the cuvette. Any moisture outside the cuvette was dried off 
and the cuvette was immediately placed into the holder of the electroporator. The 
parameters used were: 25μFD (capacitance), 200Ω (sample resistance) and 1.8 kV 
(volts). The holder was slided into position and electric current was given to cells. 
Immediately upon hearing a high constant tone (which generally occurs when the time 
37
constant is 3-4msec), 1 ml of LB was added onto cells and they were transfered into 
1.5-ml eppendorf tubes. The tubes were incubated at 37ºC for 1 hour with vigorous 
shaking. The remainder of the protocol was identical to the heat-shock method 
depicted in 3.3.1.2.1.
3.3.1.3 Long term storage of bacterial strains
To keep bacterial cells including plasmid in it or as empty for future experiments and 
to have a stock of strain in a laboratory is necessary. The most frequently used method 
is “Glycerol-Stock” method. A single colony picked from either an agar plate or a 
loop-full of bacterial stock was inoculated into 5 ml LB (with a selective agent if 
necessary) in 15 ml screw capped tubes. Tubes were incubated overnight at 37ºC and 
at 200 rpm. For glycerol stock, 500μl of saturated culture was added into 500μl of 
50% glycerol v/v (1ml autoclaved 100% glycerol, 1ml ddH2O). This mix was frozen
and stored at -80ºC.
3.3.1.4 Purification of DNA
3.3.1.4.1 Purification of plasmid DNA using MN (Macherey-Nagel) miniprep kit
This method was preferred for isolation of plasmids in order to use in sequencing or 
cloning procedures. 5 ml of saturated culture was used for isolation of plasmid DNA 
by using “MN miniprep plasmid DNA purification kit” following manufacture’s 
instructions.
3.3.1.4.2 Large-scale plasmid DNA purification
This method was used for isolation of plasmids in order to use in sequencing or 
mammalian cell transfection procedures by using “Qiagen large-scale plasmid DNA 
purification kit” and “Promega PureYield plasmid midiprep purification kit” 
following manufactures’ instructions.
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3.3.1.5 Quantification and qualification of nucleic acids
Quantification of DNA and RNA was done by NanoDrop ND-1000 Full-spectrum 
UV/Vis Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). 
Calculation of the division of OD260 and OD280 gave information about possible 
contaminants and was used to assess quality of nucleic acids.
3.3.1.6 Restriction enzyme digestion of DNA
Restriction enzyme digestions were routinely performed in 20 μl reaction volumes 
and typically 0.5-5 μg DNA was used. Reactions were carried out with the appropriate 
reaction buffer and conditions according to the manufacturer’s recommendations.
Digestion of DNA with two different restriction enzymes was performed in the same 
reaction buffer to provide the optimal condition for both restriction enzymes. If no 
single reaction buffer could be found to satisfy the buffer requirements of both 
enzymes, the reactions were carried out sequentially.
3.3.1.7 Gel electrophoresis of nucleic acids
DNA fragments were fractionated by horizontal electrophoresis by using standard 
buffers and solutions. DNA fragments less than 1 kb were generally separated on 2% 
agarose gel, those greater than 1 kb were separated on 1% agarose gels. Agarose gels 
were completely dissolved in 1x TAE electrophoresis buffer to required percentage in 
microwave and ethidium bromide was added to final concentration of 30 μg/ml. The 
DNA samples were mixed with 6x loading dye (bromophenol blue and/or xylene 
cyanol) and loaded onto gels. The gel was run in 1x TAE at different voltage and time 
depending on the size of the fragments at room temperature.
3.3.2 Computer analyses
Primers were designed by using the web software provided by Steve Rozen and 
Whitehead Institute for Biomedical Research at http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi. DUSP10 gene, mRNA and protein information were 
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obtained from National Center for Biotechnology Information website (NCBI; 
http://www.ncbi.nlm.nih.gov). SWISSPROT and TrEMBL databases listed under 
ExPASy Proteomics Server were used for bioinformatics analyses of protein domains 
and motifs (http://www.expasy.ch/sprot). Oncomine Research Platform 
(http://www.oncomine.org) was used to obtain microarray data on DUSP10. Also 
Oncogenomic Database of Hepatocellular Carcinoma was employed for obtaining 
information related to DUSP10 in hepatocellular carcinoma 
(http://oncodb.hcc.ibms.sinica.edu.tw/index.htm). Alignments of nucleic acid or 
protein sequence were performed by using NCBI BLAST at 
http://www.ncbi.nlm.nih.gov/BLAST. Multiple sequence alignments for were done by 
ClustalW2 online program at http://www.ebi.ac.uk/Tools/clustalw2/index.html. 
3.3.3 Vector construction
pEGFP-DUSP10 vector was generated by cloning the coding sequence of human 
DUSP10 transcript variant 1 mRNA (cut with BamHI and HindIII) into BglII/HindIII 
digested pEGFP-N2 vector. pcDNA3.1-DUSP10 vector was generated by cloning the 
coding sequence of human DUSP10 transcript variant 1 mRNA (cut with KpnI and 
BamHI) into KpnI/BamHI digested pcDNA3.1/myc-His B vector. As an intermediate 
step to enrich DUSP10 transcript variant 1 coding region, TA cloning was done with 
pGEMT-Easy vector system according to the kit’s specifications (Promega, Madison, 
WI, USA) and a bacterial cloning construct was obtained (pGEMT-DUSP10). All 
plasmids were verified by sequencing.
3.3.4 Tissue culture techniques
3.3.4.1 Cell lines
15 HCC derived cell lines (Huh7, Hep40, HepG2, Hep3B, Hep3B-TR [TGF-β-
resistant], PLC, Snu182, Snu387, Snu398, Snu423, Snu449, Snu475, Mahlavu, Focus 
and SK-Hep1) were used in this study and cultured as described previously (Cagatay 
T, Ozturk M, Oncogene, 2002). 8 breast cancer derived cell lines (BT-20, HCC1937, 
MCF-7, BT-474, CAMA1, T47D, MDA-MB-453 and MDA-MB-231) were also used 
and were cultivated in DMEM with 10% FBS. For experiments where a specific 
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number of cells were to be seeded, cell counting was performed by a haemocytometer 
after trypsinization and resuspension of cells in culture medium.
3.3.4.2 Thawing cell lines
One vial of the frozen cell line from the liquid nitrogen tank was taken and 
immediately put into ice. The vial was left 1 minute on the bench to allow excess 
nitrogen to evaporate and then placed into 37ºC water bath until the external part of 
the cell solution was thawed (takes approximately 1-2 minutes). The cells were 
resuspended gently using a pipette and transferred immediately into a 15 ml sterile
tube containing 10 ml cold fresh medium. The cells were centrifuged at 1200 rpm for 
3 minutes (Beckman GS-15R centrifuge, fixed angle rotor; all cell culture 
centrifugations were done with the centrifuge unless written otherwise). Supernatant 
was discarded and the pellet was resuspended in 37ºC culture medium to be plated 
into 25cm2 or 75cm2 flasks. After overnight incubation in a humidified incubator at 
37°C supplied with 5% CO2, culture mediums were replenished.
3.3.4.3 Growth conditions of cells
Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 supplemented 10% 
FCS and penicillin and streptomycin (50 mg/ml), and 1% NEAA was used to culture 
the HCC cell lines. The cells were incubated in at 37°C in an incubator with an 
atmosphere of 5% CO2 in air. The cells were passaged before reaching confluence. 
The growth medium was aspirated and the cells were washed once with calcium and 
phosphate-free PBS. Trypsin was added to the flask to remove the monolayer cells 
from the surface. The fresh medium was added and the suspension was pipetted 
gently to disperse the cells. The cells were transferred to either fresh petri dishes or 
fresh flasks using different dilutions (from 1:2 to 1:10) depending on requirements. 
All media and solutions used for culture were kept at 4°C (except stock solutions) and 
warmed to 37°C before use.
3.3.4.4 Cryopreservation of cell lines
Exponentially growing cells were harvested by trypsinization and neutralized with 
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growth medium. The cells were counted and precipitated at 1500 rpm for 5 min at 
4ºC. The pellet was suspended in a freezing solution (10% DMSO, 20% FCS and 70% 
DMEM for adherent cells; at a concentration of 4x106 cells/ml. 1 ml of this solution 
was placed into 1 ml screw capped-cryotubes. The tubes were left at -80°C overnight. 
The next day, the tubes were transferred into the liquid nitrogen storage tank.
3.3.5 Extraction of total RNA from tissue culture cells and tissue samples
Total RNAs were isolated from cultured cells using the NucleoSpin RNA II Kit (MN 
Macherey-Nagel, Duren, Germany) according to the manufacturer’s protocol.
3.3.6 First strand cDNA synthesis
First strand cDNA synthesis from total RNA was performed using RevertAid First
Strand cDNA synthesis kit (MBI Fermantas, Germany). The RevertAid kit relies on
genetically engineered version of Moloney Murine Leukemia Virus reverse 
transcriptase (RevertAid M-MuLV RT) with low RNase H activity. This allows the 
synthesis of full-length cDNA from long templates. The first strand reactions were
primed with oligo(dT)18 primer to specifically amplified mRNA population with 3’-
poly(A) tails. As the reaction conditions and components of this kit and those of 
conventional PCR are compatible, first strand synthesized with this system can be 
used as a template for PCR. 1 to 5 μg total RNA was used to synthesize the first stand 
cDNA following the manufacturer’s instruction. After 1:1 dilution of total reaction 
products in DEPC-treated water, 2 μl of diluted first strand cDNA was used for PCR.
3.3.7 Primer design for expression analysis by semi-quantitative PCR
The primer pairs that have been used in expression profile analyses were designed 
carefully. Forward and reverse primer were positioned on different exons of the gene 
of interest, so that the primer pair would either produce a longer amplicon than 
expected (from genomic DNA, if there was genomic DNA contamination in total 
RNA) or only produce the expected amplicon in a PCR reaction. The other important 
parameteres in primer design were length of expected amplicon (100-200bp), a GC 
content of about 50%, no hairpin formation, and very low energies of interactions 
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between 3’ ends of primers and primer pairs. Primers used for expression analysis 
have been designed strictly considering these criteria, and listed in Table 3.2.
Primer name Sequence Tm 
(ºC)
Number 
of cycles
DUSP10 
transcript variant 
1
F: TGCGAGTCCATAGCTGAAGA
R: CAGGAGGGTGGCTGTTACTG
62 30
DUSP10 
transcript variant 
2
F: TTGGAAGATGCTCTGGTGGT
R: TGACGTAGCCGATGTTCAGC
61 30
DUSP10 
transcript variant 
3
F: ATTTATGAAGTGGACTTAGT
R: TGACGTAGCCGATGTTCAGC
58 30
DUSP10 isoform 
a cloning 
Bam/Hind
F: TATGCAGGATCCATGCCTCCGTCTCCTTTAG
R: CCAGTAAAGCTTTCACACAACCGTCTCCACG
61 35
DUSP10 isoform 
a cloning 
Kpn/Bam
F: CAGCAAGGTACCATGCCTCCGTCTCCTTTAGAC
R: CTATAAGGATCC(GCT)CACAACCGTCTCCACGCCCAT
61 35
DUSP10 isoform 
b cloning 
Bam/EcoRV
F: AAGCTTGGATCCAATGCAGCGGCTGAACATC
R: GAATTCGATATC(GCT)CACACAACCGTCTCCAC
61 35
GAPDH
F: GGCTGAGAACGGGAAGCTTGTCAT
R: CAGCCTTCTCCATGGTGGTGAAGA
60 19
T7 for sequencing Available from İONTEK 60 -
SP6 for 
sequencing
Available from İONTEK 60 -
BGH for 
sequencing
Available from IONTEK 60 -
pEGFP-N2 
sequencing
F: CGTGTACGGTGGGAGGTCTA
R: GCTGAACTTGTGGCCGTTTA
62 -
MTMR11
F: GGGCATTCAGATGTTGTCCT
R: CTGACATAGTCCAGCCATCG
60 30
MTMR11 cloning 
Kpn/Bam
F: ATTATAGGTACCATGCCTCCCAGGGTCACCTT
R: GCGTGCGGATCC(TTA)CATCTGGTTATCCAGA
60 35
MTMR11 intron 
spanning
F: AGCTTGCCCTTTACCTCCAG
R: GCCATCTTGTTGGGACTGAT
60 30
Table 3.2: Primer list for PCR and sequencing reactions: Considering the primers for cloning, stop
codons are put inside parantheses in cases when reverse primers both with and without stop codon were 
synthesized.
3.3.8 Fidelity and DNA contamination control in first strand cDNAs
The fidelity and genomic DNA contamination of first strand cDNAs were checked 
before performing expression analyses. 2μl of diluted first strand cDNA was used for 
PCR amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
transcript. GAPDH primer pair for this analysis was designed to produce a 151 bp 
fragment from cDNA and 250 bp fragment from genomic DNA.
43
3.3.9 Expression analysis of a gene by semi-quantitative PCR and GAPDH 
normalization
Equal volume (2μl) of all first strand cDNA samples was used for PCR amplification 
of GAPDH transcript using the pre-determined optimal cycle number for GAPDH. 
Then an equal volume of each sample was loaded onto agarose gel and intensity of 
each band was analyzed by BIO-1D software. After intensities were determined,
intensity of sample with the highest densitometric reading and 2 μl loading volume 
were used as reference points for normalization of input loading volume of other 
samples for expression analysis of both GAPDH and gene of interest by PCR 
amplification. Amplification products were analyzed in computer.
3.3.10 Crude total protein extraction
Adherent monolayer cells were grown to 70% confluency in complete growth 
medium. After removal of growth medium, cells were washed twice with PBS to 
remove any serum residue. Cells were trypsinized and pelleted at 1200 rpm for 5 min 
(Beckman GS-15R centrifuge, swinging bucket rotor). Cell pellets were resuspended 
in NP40 lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% sodium
deoxycholate, 1 % NP-40, and 1X Complete Protein Inhibitor mix (Roche)) for total 
protein extraction. Complete lysis was achieved by pipetting of crude cell lysates 
several times and by incubating the lysates on ice for 30 min, and then centrifuging at 
11000xg for 30 minutes at 4ºC. Total cell protein was collected as supernatant.
For studies with phosphoproteins, the lysis buffer employed contained the following: 
10mM Tris.HCl (pH 7.6), 5mM EDTA, 50mM NaCl, 1% Triton X-100, 1X complete 
protein inhibitor mix and the phosphatase inhibitors 30mM Na-pyrophosphate, 50mM 
NaF and 100μM NaVO3. Everything else was the same as the lysis procedure with 
NP40 buffer.
3.3.11 Western blotting
The conventional Bradford protein assay was employed to quantify the protein
amounts in the lysates obtained. In this assay, known concentrations of bovine serum 
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albumin (BSA) are used to form a colored reaction with the brown Bradford reagent, 
for generation of a standard curve of OD595 vs. protein concentration. Blue color 
formation was measured at 595nm. 
After protein quantification, protein lysates were aliquoted into fresh tubes and, stored 
at -80°C. 10% resolving gel and 5% stacking gel was used in SDS-PAGE analysis of 
protein lysates. EC-120 (E-C Apparatus Corp., Holbrook, NY, USA) and ProteanII-xi 
(BioRad) vertical gel system was set up according to manufacturer’s instructions. The 
standard SDS-electrophoresis buffer system was used. Equal amounts of cell lysates 
were solubilized in 1X SDS gel-loading buffer, denatured at 100°C for 5 min and 
incubated on ice for 1 min. After a quick spin, samples were loaded onto SDS-
polyacrylamide gel. After electrophoresis at 80 V for 20 minutes followed by 120 V 
for 1-2 hours, proteins were transferred onto PVDF western blotting membrane 
(Roche) by Transblot - Wet transfer electroblotting apparatus (BioRad) according to 
the manufacturer’s instructions.
NuPAGE NOVEX pre-cast gel system from Invitrogen was also employed from time-
to-time for running a denaturing protein gel and transferring proteins onto a PVDF 
membrane, according to the manufacturer’s protocol. The gels employed were either 
4-12% or 10% Bis-Tris gels, and the running buffer employed was MOPS buffer. The 
transfer buffer employed contained 10% methanol, in accordance with the 
manufacturer’s protocol.
The resulting membrane was treated for an hour in blocking solution at room
temperature and probed with primary antibody either for an hour at room temperature 
or overnight at 4°C. After washing 4 times for (5 min, 15 min, 5 min, 5 min) in TBS-T
solution at room temperature, the membrane was incubated with appropriate HRP
conjugated secondary antibody for 1 hr. The membrane was washed 4 times for (5 
min, 15 min, 5 min, 5 min) in TBS-T solution at room temperature. After final wash, 
the blot was exposed to ECL western blot detection kit (Amersham) according to 
manufacturer’s instructions. The chemiluminescence emitted was captured on X-ray 
film within 3 sec-1 min (for proteins of high amount in cells, such as α-tubulin) to 2-
10 min (for proteins of low amount in cells, such as phosphorylated proteins) 
exposure times.
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3.3.12 SABG assay
SABG activity was detected by using a described protocol (Dimri GP. et al., 1995). 
After Nuclear Fast Red counterstaining, SABG positive and negative cells were
identified and counted.
3.3.13 Immunostaining
3.3.13.1 Immunofluorescence of cell culture monolayers
Cells were seeded onto coverslips in 6-well or 12-well plates. For experiments with 
inhibitors JNK inhibitor V, Ro-31-8220 (inhibits MKP-1), SB202190, SB203580 and
SKF86002 (inhibit p38), cells were left to attach for 24 hours at 37ºC with 5% CO2
and inhibitor was given. Control cells were not treated. Cells were left at 37ºC with 
5% CO2 for 48-72 hours before immunostaining. For experiments without inhibitors, 
cells were left overnight at 37ºC with 5% CO2 after seeding before immunostaining.
On the day of immunostaining, cells were washed with PBS twice and fixed with 3% 
paraformaldehyde in dark at room temperature for 15 minutes. After fixation, cells 
were washed with PBS once and permeabilized with 0.3% Triton X-100 in PBS for 10 
minutes at room temperature. After permeabilization, cells were washed with 150mM 
Glycine in PBS for three times with one-minute intervals. Blocking was done by 
incubating cells in 2% BSA in PBS for 1 hour at room temperature. Cells were 
washed with PBS-T (0.1% Triton X-100 in PBS) once, before the primary antibody 
(targeting the protein of interest; diluted in blocking solution) was put onto each 
coverslip. Only blocking solution was put onto negative control wells of 
immunostaining. After incubation of 2 hours at room temperature or overnight 
incubation at 4ºC, cells were washed with PBS-T three times with one-minute 
intervals. Secondary antibody (conjugated to a fluorochrome, targeting the primary 
antibody) in blocking solution was put onto each coverslip, including negative control 
wells. Cells were incubated in dark at room temperature for 1 hour and washed with 
PBS-T three times with one-minute intervals. Nuclear dye DAPI (diluted 1:10000-
20000 in ddH2O) was put into each well and cells were counterstained for 30 seconds. 
DAPI was aspirated and cells were washed with ddH2O four times. Coverslips were 
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taken out of the wells and left to air-dry for a few minutes. Meanwhile slides were 
prepared and a drop of anti-fading reagent was put on each slide. Coverslips were 
placed on slides and the edges were sealed with nail polish. Slides were observed 
under Zeiss Axio Imager.A1 or Zeiss LSM 510 (laser scanning confocal microscope), 
and stored at 4ºC in dark.
3.3.13.2 Immunoperoxidase of cell culture monolayers
Seeding and inhibitor treatment of cells were same as of immunofluorescence 
protocol. On the day of immunostaining, cells were washed with PBS twice and fixed 
with ice-cold methanol for 5 minutes or 3% formaldehyde solution for 15 minutes at 
room temperature. Ice-cold methanol also permeabilizes cells, hence no additional 
permeabilization was done when using this fixative. After fixation with formaldehyde 
however, 10-minute permeabilization with 0.3% Triton X-100 in PBS was done at 
room temperature. After fixation (and permeabilization if required), cells were washed 
with PBS twice and blocked with 10% FCS in PBS for 1 hour at room temperature. 
After washing with PBS-T (0.1% Triton X-100 in PBS) once, cells were incubated 
with primary antibody in blocking solution for 1 hour at room temperature or 
overnight at 4ºC. Only blocking solution was put onto negative control wells of 
immunostaining. Cells were washed with PBS-T three times with one-minute 
intervals and secondary antibody (conjugated to horse-radish peroxidase) were put 
onto coverslips, including negative control wells. After an incubation of 1 hour at 
room temperature, cells were washed with PBS-T three times. DAB staining solution 
was prepared during the last washing step and put on each coverslip upon aspiration 
of PBS-T. Brown staining was checked for under light microscope and color reaction 
was stopped by putting ddH2O to wells. Wells were further washed with ddH2O for 
three times. Haematoxylin was used for counterstaining of the nuclei. Cells were 
stained with haematoxylin for 10-20 seconds and washed with ddH2O for four times. 
Coverslips were taken out of the wells and left to air-dry for a few minutes. 
Meanwhile slides were prepared and a drop of 90% glycerol was put on each slide. 
Coverslips were placed on slides and the edges were sealed with nail polish. Slides 
were observed under light microscope and stored at 4ºC in dark.
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CHAPTER 4. RESULTS
4.1 DUSP10 (MKP-5)
4.1.1 Bioinformatics analysis of DUSP10
4.1.1.1 Sequence and gene information
DUSP10 stands for “dual specificity phosphatase 10”. Another alias is MKP-5 which 
stands for “mitogen-activated protein kinase phosphatase 5”. The NCBI Gene ID for 
DUSP10 is 11221. The locus in which DUSP10 gene resides is named as NC_000001 
(version 10) and it corresponds to a 249250621 bp linear DNA sequence. It has been 
mapped to the minus strand of the q arm of human chromosome 1; its exact location is 
1q41 (Fig.4.1.1). Regional loss of heterozygosity is seen in this area in HCC (Jou YS 
et al, 2004). However contradictory results come from studies aimed at uncovering 
the common genomic alterations in HCC, reporting gain of 1q in 50% of HCC 
samples analyzed and concluding that the genes located on this chromosomal arm 
may be important in early stages of hepatocarcinogenesis (Tornillo L et al, 2002).
Fig.4.1.1: Genomic context of DUSP10 gene obtained from NCBI Gene.
The gene has three transcripts, coding for two protein isoforms a and b, a being the 
dominant one. Transcript variant 1 of 2619 nucleotides (NM_007207.3) codes for 
isoform a of 482 aminoacids (NP_009138.1) and has four exons. Transcript variants 2 
and 3 of 2244 nucleotides and 1765 nucleotides (NM_144728.1 and NM_144729.1, 
respectively) code for isoform b of 140 aminoacids (can be accessed both by 
NP_653329.1 and NP_653330.1) and have three exons each. Transcript variant 2 has 
a unique untranslated exon that the other variants lack (Fig.4.2). Transcript variants 1 
and 3 only differ in that variant 1 has an extra coding exon (Fig.4.2). The translated 
region of transcript variant 1 is 1449 basepairs (bp) long whereas translated regions of 
transcript variant 2 and 3 are 423 bp long.
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Fig.4.1.2: Locus, transcripts and protein isoforms of DUSP10 obtained from NCBI Gene: RT-PCR 
primers designed for different DUSP10 transcript variants are also depicted on the figure (black 
arrows): Second exon (forward primer) of T.V. 1 (which is specific to this variant) and third exon 
(reverse primer) were employed for T.V. 1-specific (shown in the middle) primer pair design. First exon
(forward primer) of T.V. 2 (which is specific to this variant) and first-second exon boundary (reverse 
primer) were employed for T.V. 2-specific (shown in the bottom of the figure) primer pair design. First 
exon (forward primer) and first-second exon boundary (reverse primer) were employed for T.V. 3-
specific (uppermost in the figure) primer pair design.
Additionally, 188 SNPs (single nucleotide polymorphisms) have been reported in 
GeneCards database so far for DUSP10 gene (Rebhan M et al, 1998). Most SNPs are 
intronic or located in the untranslated regions. There are three synonymous and there 
aren’t any non-synonymous SNPs located in this gene.
4.1.1.2 Protein information
4.1.1.2.1 General information
DUSP10 isoform a is represented in SWISS-PROT Database by Q9Y6W6-1 symbol 
and it consists of 482 aminoacids, corresponding to a molecular weight of 52642 
Daltons and a theoretical isoelectric point (pI) of 7.87. DUSP10 isoform b is 
represented by Q9Y6W6-2 symbol and it consists of 140 aminoacids, corresponding 
to a molecular weight of 16110 Daltons and a theoretical pI of 8.89.
The two protein isoforms differ at N-terminus and are identical at C-terminus. Hence 
the only difference between them is the extra 342 aminoacids in DUSP10 isoform a. 
DUSP10 belongs to a subfamily of phosphatases named as MAPK phosphatases 
which are dual specificity phosphatases that can dephosphorylate both serine-
threonine and tyrosine residues on MAPKs, inactivating them. It is also highly 
conserved among the species that encode it (human, mouse, rat, cow, dog, chimpanzee 
and chicken).
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4.1.1.2.2 Protein domains and motifs
DUSP10 is known to be a dual specificity phosphatase and thus contains such a 
catalytic domain according to Motif Scan search (Fig.4.1.3a and b). Isoform a also 
contains a catalytically inactive rhodanese domain which is thought to determine 
substrate specificity by binding the substrate and activating the C-terminal catalytic 
domain by inducing a conformational change. According to NCBI Conserved 
Domains search, putative substrate binding residues are found within this domain 
(Fig.4.1.4). SWISS-PROT database classifies DUSP10 as a “phosphoprotein,” 
according to an article in which phosphoproteome of the human mitotic spindle has 
been analyzed by mass spectrometry. In this study, phosphorylation of DUSP10 
isoform a at serine-4 has been observed (Nousiainen M et al, 2006). Interestingly, 
according to Motif Scan search, a possible casein kinase II phosphorylation site 
contains this residue. The “possible” sites given by Motif Scan search are weak 
matches as they are motifs that are frequently found in other proteins and may not be 
specific to DUSP10. However the information that Ser-4 is phosphorylated 
strengthens the possibility of casein kinase II phosphorylation at this residue. The 
Java-based online software GPS (Group-based prediction system) 2.1 from CUCKOO 
Workgroup predicts phosphorylation by many kinases at this residue, especially by 
CMGC (containing CDK, MAPK, GSK3, CLK families) kinase family (Xue Y et al, 
2008).
Dual specificity phosphatase active site signature motif is [I/V]HCXAGXSR[S/T]X-
TXXXAY[I/L]M, where X is any amino acid. This motif is IHCQAGVSRSA-
TIVIAYLM for DUSP10. This is like an extended tyrosine phosphatase signature 
motif and the dash separates this motif and its extension.
Although the possible N-myristoylation sites infer a membrane-associated localization 
for DUSP10, its localization has been determined as “cytoplasm and nucleus” by 
different studies (Tanoue T et al, 1999; Theodosiou A et al, 1999). 
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Fig.4.1.4: NCBI Conserved Domain result for DUSP10 isoform a: Putative substrate binding 
residues are marked with blue triangles. Active site and catalytic residues are marked with red triangles. 
RHOD: Rhodanese homology domain, DSPc: Dual specificity phosphatase catalytic domain.
4.1.1.2.3 Protein structure
Secondary-structure information on DUSP10 isoforms was obtained by querying at 
NPS (Network Protein Sequence Analysis) database using PHD (Rost B, Sander C, 
1994), DSC (King RD, Stenberg MJ, 1996) and MLRC on GOR4, SIMPA96 and 
SOPMA (Guermeur Y et al, 1999) prediction methods. According to this, DUSP10 
isoform a contains 22.2% alpha helices, 17.84% extended strands and 59.54% random 
coils (Fig.4.1.5a), and, DUSP10 isoform b contains 40% alpha helices, 14.29% 
extended strands and 45.71% random coils (Fig.4.1.5b).
Fig.4.1.5a: NPS consensus secondary structure prediction for DUSP10 isoform a: Red parts mark 
the extended strands, blue parts mark the alpha helices, and purple parts mark the random coils. Alpha 
helices are associated with functional domains. In addition to the above figure, SWISS-PROT database 
predicts a turn at position 277-279.
Fig.4.1.5b: NPS consensus secondary structure prediction for DUSP10 isoform b: Red parts mark 
the extended strands, blue parts mark the alpha helices, and purple parts mark the random coils. Alpha 
helices are associated with the functional domain.
In one study, tertiary structures of MAPK binding domain (also known as rhodanese 
domain; PDB ID: 2OUC) and catalytic domain (PDB ID: 2OUD) of DUSP10 have 
been determined by X-Ray diffraction (Tao X, Tong L, 2007). These are shown in 
Fig.4.1.6a and b, respectively.
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Fig.4.1.6: a. 3D structure of DUSP10 rhodanese domain, b. 3D structure of DUSP10 catalytic 
domain.
4.1.1.3 Gene homologs and protein sequence conservation
4.1.1.3.1 Orthologs of DUSP10
According to HomoloGene Database of NCBI, orthologs of DUSP10 exist in seven 
other species. This database only gives results for isoform a. These species, and the 
extent of identity between their DUSP10 genes/proteins and Homo sapiens DUSP10 
gene/protein is listed in Table 4.1.1.
Table 4.1.1: Orthologs of human DUSP10 and multiple alignment pair-wise similarity scores
between DUSP10 protein and DNA sequences of different species.
The multiple sequence alignment of the protein sequences of these orthologs were 
generated using ClustalW2 (Thompson JD et al, 1997). Fig.4.1.7 shows the conserved 
a b
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residues among different species. The sequences aligned from top to bottom belong to 
Homo sapiens (human), Pan troglodytes (chimpanzee), Mus musculus (mouse), 
Rattus norvegicus (rat), Bos taurus (cow), Canis lupus familiaris (dog) and Gallus 
gallus (chicken), respectively. When Danio rerio is not considered the extent of 
conservation among the remaining species is clearly seen (Fig.4.1.7).
High conservation is seen in the N-terminus of DUSP10 orthologs (the first 30 
residues are identical among all except Danio rerio), in the regulatory rhodanese 
domain (except Danio rerio which seems to lack this domain) and in the dual 
specificity phosphatase catalytic domain (in all of the species). Other short sequences 
of highly conserved amino acid residues may indicate important regulatory residues.
The Serine residue at position 4, which has been found to be phosphorylated as 
already mentioned, is conserved in all species except Danio rerio (a leucine residue is 
found instead of serine in this species). Since Danio rerio lacks also the regulatory 
rhodanese domain (MAPK binding domain), the phosphorylation of this residue may 
be important in substrate binding and specificity.
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Fig.4.1.7: ClustalW2 multiple sequence alignment of DUSP10 orthologs except the Danio rerio 
ortholog: From top to bottom: Human, chimpanzee, mouse, rat, cow, dog and chicken orthologs are 
listed.
4.1.1.3.2 Paralogs of DUSP10
DUSP10 belongs to a phosphatase subfamily named as MAPK phosphatases under 
the family dual specificity phosphatases, as already mentioned. A dendrogram 
showing the relations of most DSPs are shown in Fig.4.1.8. Additional information 
come from studies. A tree showing the relations of most MKPs are shown in Fig.4.1.9. 
The conserved domains in MKP paralogs are shown in Fig.4.1.10.
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Fig.4.1.8: Phylogenetic tree of DUSP gene family with branch lengths: Includes only human genes. 
Paralogs are gathered by KEGG SSDB paralog search. Phylogenetic tree is generated by MAFFT 
sequence alignment.
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Fig.4.1.9: Cluster of MKPs according to substrate preference: Inducible nuclear group also targets 
ERK MAPK (Dickinson RJ, Keyse SM, 2006).
Fig.4.1.10: Conserved motifs in MKPs: Same color code is used as Fig.4.1.9 (beige marks the 
inducible nuclear group, light purple marks the cytoplasmic ERK-selective group, and blue marks the 
JNK/p38-selective group). DUS24/MK-STYX is an atypical MKP that is catalytically inactive (hence 
its catalytic site is shown in grey in contrast to the dark purple active catalytic sites). NLS: nuclear 
localization signal; NES: nuclear exclusion signal; KIM: kinase interacting motif; PEST: Proline-
Glutamate-Serine-Threonine motif, associated with rapidly-degraded proteins (Dickinson RJ, Keyse 
SM, 2006).
As indicated in Fig.4.1.10, DUSP10 has an unusual proline-rich N-terminal sequence 
that is not seen in any other MKP. There are no regulatory domains associated with 
this sequence of about 100 amino acids yet. Since orthologous proteins from other 
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species also bear this unusual N-terminal sequence and is highly conserved among 
many of these species, important but uncharacterized motifs may be present here, 
such as an unknown nuclear localization signal, since generally MKPs are known to 
dephosphorylate MAPKs in both cytoplasm and nucleus.
4.1.1.4 DUSP10 in gene expression profiling arrays
Oncomine Cancer Profiling Database was used to check DUSP10 expression changes 
in different microarrays comparing HCC tissues with non-tumorous tissues. Box-plots 
were generated upon selection of relevant results. These are shown in Fig.4.1.11.
There are two main microarray studies on HCC in Oncomine Database: Chen_Liver 
and Wurmbach_Liver. Chen_Liver is published by Chen X et al in 2002. This study 
aims at finding the gene expression patterns which distinguish between primary 
human liver cancers and cancers that metastasize to liver. Wurmbach_Liver is 
published by Wurmbach E et al in 2007. It aims at characterizing the genome-wide 
molecular profiles of different liver disease and cancer states, for biomarker discovery 
purposes. Of these two important studies, DUSP10 gave significant results in only 
Wurmbach_Liver (normal vs. disease state). In this study, the expression of DUSP10 
was significantly reduced in HCC samples compared to normal tissues.
    
Fig.4.1.11. DUSP10 expression in Wurmbach microarray data: Left, normal (Class 1, n=10) vs 
HCC (Class 2, n=35), p=0.002. Right, normal (Class 1, n=10) vs dysplastic tissue (Class 2, n=17), 
p=0.01.
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The fact that DUSP10 emerged as a gene downregulated in immortal clones and the 
above finding strengthen the possibility that a relationship between DUSP10 and 
hepatocarcinogenesis exists and it is possible that DUSP10 may act as a tumor 
suppressor in HCC.
4.1.1.5 Expression data
On the UCSC (University of California, Santa Cruz) Genome Browser website, the 
expression data of DUSP10 isoform a can be obtained from several microarray 
studies. The data gathered from the GNF Expression Atlas 2 human data on Affy 
U133A and GNF1H chips (Su AI et al, 2002), where red represents high expression 
level and green represents low expression level, is as follows:
Fig.4.1.12: Expression data of DUSP10 based on the GNF Expression Atlas 2 Data from U133A 
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and GNF1H Chips.
According to this expression data, although generally all tissues and cells tested 
expressed DUSP10 to a certain level (as hinted at by the dominance of the black 
color), it is expressed more in a number of differentiated immune system and 
hematopoietic cell types, B-lymphoblasts, bronchial epithelial cells and adult liver. 
Relatively low levels of DUSP10 is detected in uterus corpus, kidney and colorectal 
adenocarcinoma.
4.1.2 Analysis of DUSP10 expression change between senescent and immortal 
Huh7 clones
As a first step, we performed PCR to verify DUSP10 differential expression obtained 
by the microarray study previously done by our group in C1, C3-Early and C3-Late 
clones (see Introduction chapter, section 1.5). The result of this PCR and a graph
displaying the relative expression of DUSP10 in each clone are shown below:
Fig.4.1.13a: DUSP10 is upregulated in senescent and revertant clones compared to the immortal 
clone: cDNA from C1 (immortal clone), C3-Early (revertant clone) and C3-Late (senescent clone) 
were used for semi-quantitative RT-PCR experiments. GAPDH: Glyceraldehyde-3-phosphate 
dehydrogenase was used as an internal control. (-): Negative control well to check for nucleic acid 
contaminants. A Western blot of these clones against DUSP10 was not done due to lack of proteins.
    C1      C3E     C3L     (-)
DUSP10
GAPDH
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Fig.4.1.13b: DUSP10 is upregulated in senescent and revertant clones compared to the immortal 
clone: A graph was generated by normalization of DUSP10 band intensities according to GAPDH band 
intensities in Fig.4.1.13a. Intensities were quantified by Bio-1D program.
The results shown in Fig.4.1.13a and b indicate that DUSP10 expression is increased 
progressively from C1 immortal clone to C3 senescent clone. There is a deviation 
from the fold changes observed in the original microarray data (2.5 fold increase in 
revertant vs immortal clone and 2.6 fold increase in senescent vs immortal clone). 
This may be due to the method of band intensity measurement or due to the 
insensitivity of the semi-quantitative PCR. Still, it is clearly seen that DUSP10 is 
upregulated in senescent cells in contrast to immortal ones.
4.1.3 DUSP10 expression data
We then continued our analysis on DUSP10 by generating DUSP10 mRNA and 
protein expression data in HCC and breast cancer cell lines (Fig.4.1.14a and b). For 
this purpose, cDNAs from various HCC and breast cancer cell lines were extracted 
and used in semi-quantitative RT-PCR. Also proteins were extracted from HCC cell 
lines and used in Western Blot.
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GAPDH
DUSP10
Huh7 Hep40 Hep        Hep       Hep      PLC       Snu Snu Snu Snu Snu Snu SK Mahlavu Focus (-)
G2 3B 3B-TR                   182       387 398 423 449        475      Hep 1                            
Fig.4.1.14a: Upper, DUSP10 transcript variant 1 mRNA levels in HCC cell lines: Huh7, Hep40, 
HepG2, Hep3B, Hep3B-TR, PLC are classified as well-differentiated cell lines. Snu182, Snu387, 
Snu398, Snu423, Snu449, Snu475, SK Hep1, Mahlavu and Focus are classified as poorly differentiated 
cell lines. GAPDH was used as an internal control. (-) well showed no contamination. Lower, DUSP10
protein levels in HCC cell lines: Tubulin (Tub) was used as an internal control. Western blotting was 
done as described in Materials and Methods.
BT20       HCC 1937      MCF-7   BT474        CAMA I        T47D     MDA MB-453 MDA MB-231     (-)
GAPDH
DUSP10
Fig.4.1.14b: DUSP10 transcript variant 1 mRNA levels in selected breast cancer cell lines: BT20 
and HCC 1937 are classified as basal cell lines. MCF-7, BT474, CAMAI, T47D and MDA MB-453 are 
classified as luminal cell lines. MDA MB-231 is classified as a mesenchymal cell line. GAPDH was 
used as an internal control. (-) well showed no contamination.
These results indicate that DUSP10 transcript variant 1 is expressed in all HCC cell 
lines and breast cancer cell lines tested, although heterogenously. At this step, 
DUSP10 transcript variant 2 and 3 did not show any expression (Fig.4.1.15a and b, 
respectively). Since, in mice, the second transcript variant of DUSP10 (possibly 
representing human DUSP10 isoform b coding transcript variants) has been found to 
be specifically expressed in testis according to OMIM, this result may have been 
expected (Masuda K et al, 2000). Hence all the following experiments were done on 
DUSP10 transcript variant 1 or isoform a.
Fig.4.1.15a: DUSP10 transcript variant 2 is not expressed in HCC cell lines: From left to right, 
Huh7, Hep40, HepG2, Hep3B, PLC, Snu387, Snu475, Focus, Mahlavu and (-) control were loaded. 
The expected product was 197 bp long. This image shows 100-500bp region of the gel.
Tub
Dusp10
  Huh7     Hep40      Hep         Hep       Hep          PLC        Snu        Snu       Snu       Snu        Snu         Snu         SK      Mahlavu  Focus
                                  G2          3B      3B-TR                        182         387        398        423         449         475       Hep 1                            
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Fig.4.1.15b: DUSP10 transcript variant 3 is not expressed in HCC cell lines: From left to right, 
Huh7, HepG2, Hep3B, Snu387, Snu449, Focus, Mahlavu and (-) control were loaded. The expected 
product was 176 bp long. This image shows 100-500bp region of the gel.
4.1.4 Subcellular localization of DUSP10 in hepatocellular carcinoma cell lines
4.1.4.1 Localization of DUSP10 changes between different cell lines
As seen above, no significant DUSP10 expression changes are observed between 
well- and poorly-differentiated HCC cell lines. The morphology of well-differentiated
cell lines (eg. HepG2 and Hep3B) is more similar to normal hepatocytes compared to 
poorly-differentiated cell lines (eg. Snu182 and Mahlavu) and they express α-
fetoprotein (AFP) which is a useful marker for post-treatment monitoring of HCC 
patients (eg. for treatment efficacy or tumor recurrence). Well-differentiated HCC cell 
lines are also called as epithelial-like as opposed to mesenchymal-like poorly-
differentiated cell lines, due to the epithelial/mesenchymal markers they express or do 
not express. Since DUSP10 is important according to our group’s microarray data, we 
wondered if a DUSP10-related difference between these two types of cell lines is 
present in another aspect. One such aspect, subcellular localization, also gives 
substantial clues on the function of a protein. Hence we checked subcellular 
localization of DUSP10 in HCC by immunoperoxidase staining and by 
immunofluorescence. Results are shown in Fig.4.1.16 and Fig.4.1.17, respectively.
The results of immunoperoxidase staining is summarized in Table 4.1.2. Staining 
intensities and patterns are indicated for each cell line. Generally the cytoplasmic 
staining seen in cell lines were concentrated on the immediate perimeter of the nuclei. 
    Cell Line
Pattern
Huh
7
Hep
40
Hep
G2
Hep
3B
Hep
3B-TR
PLC Snu
182
Snu
387
Snu
398
Snu
423
Snu
449
Snu
475
Mahlavu Focus SK
Hep1
Cytoplasmic ++ ++ ++ ++ ++ ++ + + +++ + ++ ++ +++ ++ ++
Nuclear + +/- + +/- +/- +/- ++ - + - +/- + + + +/-
Peri-nuclear + + - ++ +/- +/- - + ++ + ++ ++ +++ ++ +
Table 4.1.2: DUSP10 staining patterns of 15 HCC cell lines according to immunoperoxidase 
staining: The number of (+)s indicates the intensity of staining. Peri-nuclear staining is positive if 
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some or most of the cytoplasmic staining is observed in close proximity with the nuclei compared to 
other parts of cytoplasm. 
Fig.4.1.16: DUSP10 immunostaining in HCC cell lines: Cells were seeded on coverslips in 50-80% 
confluency and left to grow overnight at 37ºC with 5% CO2. Immunoperoxidase staining was 
performed as explained in Materials and Methods. No primary antibodies were put onto (-) controls. 
Background staining due to the HRP-bound secondary antibody was assessed this way. All sample and 
negative control pairs were photographed with the same light exposure and under 40x objective, to 
avoid bias. The results continue in the following pages.
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Fig.4.1.16 (continued): DUSP10 immunostaining in HCC cell lines: Cells were seeded on coverslips 
in 50-80% confluency and left to grow overnight at 37ºC with 5% CO2. Immunoperoxidase staining 
was performed as explained in Materials and Methods. No primary antibodies were put onto (-) 
controls. Background staining due to the HRP-bound secondary antibody was assessed this way. All 
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sample and negative control pairs were photographed with the same light exposure and under 40x 
objective, to avoid bias.
We obtained similar results with immunofluorescence. The results of 
immunofluorescence is shown in Table 4.1.3. Although deviations from 
immunoperoxidase staining data are seen, generally both results are in correlation. 
Again, the cytoplasmic staining seen in cell lines mostly concentrate in the peri-
nuclear region. Since this staining pattern is seen in proteins that localize to the 
endoplasmic reticulum (ER), we designed our next experiment as a DUSP10/Calnexin 
co-staining in Snu423 cell line in which peri-nuclear DUSP10 staining is clearly seen.
    Cell Line
Pattern
Huh
7
Hep
40
Hep
G2
Hep
3B
Hep
3B-TR
PLC Snu
182
Snu
387
Snu
398
Snu
423
Snu
449
Snu
475
Mahlavu Focus SK
Hep1
Cytoplasmic + + + ++ + + + + ++ ++ ++ ++ + + ++
Nuclear + + ++ +/- + ++ ++ ++ +/- + +/- +/- ++ + +/-
Peri-nuclear +/- +/- + ++ +/- +/- + +/- + + + ++ + + ++
Table 4.1.3: DUSP10 staining patterns of 15 HCC cell lines according to immunofluorescence:
The number of (+)s indicates the intensity of staining. Peri-nuclear staining is positive if some or most 
of the cytoplasmic staining is observed in close proximity with the nuclei compared to other parts of 
cytoplasm. 
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Fig.4.1.17: DUSP10 immunofluorescence in HCC cell lines: Cells were seeded on coverslips in 50-
80% confluency and left to grow overnight at 37ºC with 5% CO2. Immunofluorescence was performed 
as explained in Materials and Methods. Each sample has three photographs (through DAPI and Alexa 
Fluor 568 / TRITC filters, and the merge of these two photos). Merge (-) stands for the merged image 
of negative control for each sample. No primary antibodies were put onto (-) controls. Background 
staining due to the fluorochrome-bound secondary antibody was assessed this way. All sample and 
negative control pairs were photographed with the same fluorescence exposure and under 40x 
objective, to avoid bias. Tiny bright red dots seen in some images might be related to secondary 
antibody degradation. The results continue in the following pages.
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Fig.4.1.17 (Continued): DUSP10 immunofluorescence in HCC cell lines: Cells were seeded on 
coverslips in 50-80% confluency and grown overnight at 37ºC with 5% CO2. Immunofluorescence was 
performed as explained in Materials and Methods. Each sample has three photographs (through DAPI 
and Alexa Fluor 568 / TRITC filters, and the merge of these two photos). Merge (-) stands for the 
merged image of negative control for each sample. No primary antibodies were put onto (-) controls. 
Background staining due to the fluorochrome-bound secondary antibody was assessed this way. All 
sample and negative control pairs were photographed with the same fluorescence exposure and under 
40x objective, to avoid bias. Tiny bright red dots seen in some images might be related to secondary 
antibody degradation. The results continue in the following pages.
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Fig.4.1.17 (Continued): DUSP10 immunofluorescence in HCC cell lines: Cells were seeded on 
coverslips in 50-80% confluency and grown overnight at 37ºC with 5% CO2. Immunofluorescence was 
performed as explained in Materials and Methods. Each sample has three photographs (through DAPI 
and Alexa Fluor 568 / TRITC filters, and the merge of these two photos). Merge (-) stands for the 
merged image of negative control for each sample. No primary antibodies were put onto (-) controls. 
Background staining due to the fluorochrome-bound secondary antibody was assessed this way. All 
sample and negative control pairs were photographed with the same fluorescence exposure and under 
40x objective, to avoid bias. Tiny bright red dots seen in some images might be related to secondary 
antibody degradation. The results continue in the following pages.
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Fig.4.1.17 (Continued): DUSP10 immunofluorescence in HCC cell lines: Cells were seeded on 
coverslips in 50-80% confluency and grown overnight at 37ºC with 5% CO2. Immunofluorescence was 
performed as explained in Materials and Methods. Each sample has three photographs (through DAPI 
and Alexa Fluor 568 / TRITC filters, and the merge of these two photos). Merge (-) stands for the 
merged image of negative control for each sample. No primary antibodies were put onto (-) controls. 
Background staining due to the fluorochrome-bound secondary antibody was assessed this way. All 
sample and negative control pairs were photographed with the same fluorescence exposure and under 
40x objective, to avoid bias. Tiny bright red dots seen in some images might be related to secondary 
antibody degradation. The results continue in the following pages.
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Fig.4.1.17 (Continued): DUSP10 immunofluorescence in HCC cell lines: Cells were seeded on 
coverslips in 50-80% confluency and grown overnight at 37ºC with 5% CO2. Immunofluorescence was 
performed as explained in Materials and Methods. Each sample has three photographs (through DAPI 
and Alexa Fluor 568 / TRITC filters, and the merge of these two photos). Merge (-) stands for the 
merged image of negative control for each sample. No primary antibodies were put onto (-) controls. 
Background staining due to the fluorochrome-bound secondary antibody was assessed this way. All 
sample and negative control pairs were photographed with the same fluorescence exposure and under 
40x objective, to avoid bias. Tiny bright red dots seen in some images might be related to secondary 
antibody degradation.
4.1.4.2 DUSP10 does not co-localize with calnexin, an ER-membrane protein, in 
cell lines showing peri-nuclear / cytoplasmic DUSP10 staining
Our next experiment aimed at finding if DUSP10 localized to an organelle, 
specifically to ER. For this purpose, we chose an HCC cell line, Snu423, in which 
perinuclear DUSP10 localization was clear. Results are shown in Fig.4.1.18.
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Fig.4.1.18: DUSP10 and calnexin co-staining in Snu423: Cells were seeded on coverslips in 50-80% 
confluency and left to grow overnight at 37ºC with 5% CO2. Immunofluorescence was performed as 
explained in Materials and Methods. Although the red color generated by DUSP10 bound Alexa Fluor 
568 turned to orange after merge with the green color generated by calnexin bound Alexa Fluor 488, 
essentially everywhere, there were extra green coloring in some places in each cell. Also some patterns 
of green did not match the corresponding patterns of red. These unmatching patterns of green are 
shown with white arrows.
Since there were regions in cells where only green staining was seen, we could say 
that DUSP10 is not localized to ER. The orange staining due to the faint green 
staining (Calnexin) coinciding with the stronger red staining (DUSP10) can be 
because of the channel cross-talk mediated when two fluorochromes with overlapping 
spectra, such as Alexa Fluor 488 (green) and 568 (red), are employed.
Next, we decided to take photographs through confocal microscopy because 3D 
images (images from the same z-plane) would give better information about the 
localization of a protein (Fig.4.1.19a, b and Fig.4.1.20a, b). Additionally, with the 
confocal microscope, adjustments can be made so as to overcome the channel cross-
talk that is mentioned above.
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Fig.4.1.19a: Confocal image of DUSP10/Calnexin costaining, the plane where DUSP10 staining is 
the highest (40x), b: the plane where Calnexin staining is the highest (40x): All confocal images are 
taken at Zeiss LSM 510 laser scanning confocal microscope at Middle East Technical University. It is 
clearly seen that Calnexin and DUSP10 stainings exclude each other. The cell marked with white 
arrows is photographed with higher magnification in Fig.4.1.20a and b.
Fig.4.1.20a. Confocal image of DUSP10/Calnexin costaining, the plane where DUSP10 staining is 
the highest (80x), b. (160x): It is clearly seen that Calnexin and DUSP10 staining do not overlap. In b, 
the view was rotated so that the magnified cell fit the frame. In this specific cell, peri-nuclear DUSP10 
staining is not very clear as a diffuse cytoplasmic staining is seen.
According to these results, it was verified with the confocal microscope that DUSP10 
did not colocalize with Calnexin to endoplasmic reticulum.
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4.1.4.3 DUSP10 co-localizes with beta-actin, a cytoskeletal protein, in cell lines 
showing peri-nuclear / cytoplasmic DUSP10 staining
Since DUSP10 staining was observed as a meshwork of thin lines in the cytoplasms in 
Fig.4.1.20a-b, we checked to see if DUSP10 colocalizes with Actin. The results 
showed that DUSP10 and Actin colocalize in cytoplasm (Fig.4.1.21). 
      
Fig.4.1.21: DUSP10/Actin and DUSP10/Calnexin staining in Snu182 cell line (40x): Actin antibody 
used stains the nucleoli, too, with great intensity. Except nucleoli, DUSP10 and Actin staining overlap 
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completely. In the group of images on the right, it can be seen that DUSP10 and Calnexin staining 
exclude each other completely in Snu182 cell line (which shows nuclear DUSP10 localization).
After these colocalization experiments, we concluded that DUSP10 localizes to the 
cytoplasm in most HCC cell lines and to the nucleus in others. The cytoplasmic 
DUSP10 tends to stack immediately around the nucleus in most cell lines that show 
cytoplasmic DUSP10 staining. In the others (Snu449 and SK-Hep1), the cytoplasmic 
DUSP10 tends to aggregate in bright foci. These specific clusterings of DUSP10 
might be important in aiding its nuclear translocation when required.
4.1.5 Assesment of factors that may have an effect on DUSP10 localization
The observation that DUSP10 localizes to nuclei in some cell lines encouraged us to 
search for the factors that may be regulating and changing the subcellular localization 
of DUSP10.
4.1.5.1 Effect of senescence induction on DUSP10 localization
We checked if subcellular localization of DUSP10 changed in cells where senescence 
is induced either as a consequence of proliferative life spans of normal cells, or with 
senescence-inducing agents. We were especially interested in seeing if DUSP10 
localization changes in replicative senescence, since DUSP10 is implicated as a 
senescence-associated phosphatase in our microarray data.
4.1.5.1.1 Nuclear translocation is seen in late passage MRC-5 fibroblasts 
compared to early passage cells
We employed MRC-5 embryonic fibroblast cell line as a non-cancerous cell line to 
check if DUSP10 localization changes in early passages (passage 16) compared to late 
passages (passage 30) of these cells. 
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Fig.4.1.22: Effect of replicative senescence on DUSP10 subcellular localization (40x): In early 
passage fibroblasts (p.16) the nuclei are mostly blue due to hematoxylin counterstaining, whereas in 
late passage fibroblasts (p.30) the nuclei are mostly brown hinting at DUSP10 staining inside. 
Additionally, the enlargened morphology of late passage fibroblasts associated by senescence is clearly 
seen.
The result was promising, as DUSP10 localization seemed to be primarily in the 
cytoplasms of proliferating fibroblasts (p.16) compared to DUSP10 staining evenly in 
both cytoplasms and nuclei of aging cells (p.30) (Fig.4.1.22).
4.1.5.1.2 Camptothecin and TGF-β, senescence-inducing agents, do not have an 
effect on DUSP10 localization
We also checked if DUSP10 localization changes due to premature senescence 
induced by camptothecin (CPT) or TGF-β in Huh7 cell line. For this purpose, Huh7 
cells were treated with 5ng/ml TGF-β, 10nM or 50nM CPT for four days before 
SAβG assay followed by DUSP10 immunostaining was performed. The 
concentrations for these reagents were determined by previous studies of our group 
(Şentürk Ş et al, unpublished data; Bilget-Güven E et al, unpublished data). The
results are shown in Fig.4.1.23 and 4.1.24.
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Fig.4.1.23: Effect of camptothecin on DUSP10 subcellular localization (40x): Nuclear DUSP10
(black arrow) and SAβG staining (green arrows) do not overlap. No counterstaining was done to 
prevent possible interference with the brown immunostaining.
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Fig.4.1.24: Effect of TGF-β on DUSP10 subcellular localization (40x): Nuclear DUSP10 (black 
arrows) and SAβG staining (green arrow) do not overlap. No counterstaining was done to prevent 
possible interference with the brown immunostaining.
These results indicate that DUSP10 localization shifts to nuclei due to replicative 
senescence, however it is not affected by premature senescence. We moved on to 
assess one more factor that may regulate the subcellular localization of DUSP10.
4.1.5.2 Effect of JNK and p38 MAPK inhibitors on the subcellular localization of 
DUSP10
Next, we reasoned that disruption of the pathways in which DUSP10 functions
(Fig.4.1.25a-b), by kinase inhibitors, could have an effect on its subcellular 
localization through feedback regulation. For this purpose, we treated Hep3B and
Snu182 cell lines with JNK and p38 inhibitors for three days and performed DUSP10 
immunostaining. All these inhibitors are ATP-competitive, meaning they do not affect 
phosphorylation (and thus activation) of these kinases, but they disrupt the 
transmission of signal to downstream elements of the pathway by blocking 
phosphorylation of target proteins by the kinases.
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The concentrations of inhibitors used were determined by our group’s drug screening
results which is also a branch of KANİLTEK project (performed on HCC cell lines to 
assess the cytotoxicity or proliferative arrest induced by a wide array of commercial 
kinase inhibitors) (Bilget-Güven E et al, unpublished).
Fig.4.1.25a: Simplified JNK pathway and its possible feedback regulatory mechanism: JNK is 
phosphorylated at Thr-183 and Tyr-185 by MKK4/7. This is reversed by a number of phosphatases 
including DUSP10. Phosphorylated JNK acts on a variety of transcription factors in nucleus, such as c-
Jun and ATF-2. These transcription factors form homo- or heterodimers which are collectively known 
as AP-1 transcription factor complexes. These complexes act on target promoters. MKP promoters are 
thought to be among these targets. Hence upon activation of JNK, a negative feedback loop is thought 
to form to control its activity (Teng CH et al, 2007).
Fig.4.1.25b: Simplified p38 pathway and its possible feedback regulatory mechanism: p38 is 
phosphorylated at Thr-180 and Tyr-182 by MKK3/6. This is reversed by a number of phosphatases 
including DUSP10. Phosphorylated p38 acts on a variety of transcription factors in nucleus, such as 
ATF-2. This transcription factor form homodimers with another ATF-2 or heterodimers with other 
transcription factors, and these dimers are collectively known as AP-1 transcription factor complexes. 
These complexes act on target promoters. MKP promoters are thought to be among these targets. 
Hence upon activation of p38, a negative feedback loop may be generated to control its activity (see 
Krishna M, Narang H, 2008).
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Fig.4.1.26a: Effect of JNK and p38 inhibitors on DUSP10 localization in Hep3B cell line (40x):
Each inhibitor was used at its median inhibition concentration (IC50) and at the half of this 
concentration. To minimize the differences in staining due to procedural errors and changes, each 
inhibitor-treated sample is compared to its control and not to the other inhibitors’ samples or controls. 
The arrows show examples of cells that we consider as having nuclear DUSP10. The results continue 
in the next page.
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Fig.4.1.26a (continued): Effect of JNK and p38 inhibitors on DUSP10 localization in Hep3B cell 
line (40x): Each inhibitor was used at its median inhibition concentration (IC50) and at the half of this 
concentration. To minimize the differences in staining due to procedural errors and changes, each 
inhibitor-treated sample is compared to its control and not to the other inhibitors’ samples or controls. 
The arrows show examples of cells that we consider as having nuclear DUSP10.
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Fig.4.1.26b: Effect of JNK and p38 inhibitors on DUSP10 localization in Snu182 cell line (40x):
Each inhibitor was used at its median inhibition concentration (IC50) and at the half of this 
concentration. To minimize the differences in staining due to procedural errors and changes, each 
inhibitor-treated sample is compared to its control and not to the other inhibitors’ samples or controls. 
The results continue in the next page.
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Fig.4.1.26b (continued): Effect of JNK and p38 inhibitors on DUSP10 localization in Snu182 cell 
line (40x): Each inhibitor was used at its median inhibition concentration (IC50) and at the half of this 
concentration. To minimize the differences in staining due to procedural errors and changes, each 
inhibitor-treated sample is compared to its control and not to the other inhibitors’ samples or controls. 
As can be seen in Fig.4.1.26a, JNK inhibitor V affected DUSP10 localization in 
Hep3B cell line where normally cytoplasmic DUSP10 is seen. The effects of p38 
inhibitors were negligible. JNK inhibitor V treatment followed by DUSP10 
immunostaining was also performed in Huh7, HepG2 and Mahlavu cell lines. The 
results are shown in Fig.4.1.27.
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Fig.4.1.27: Effect of JNK inhibitor V on DUSP10 localization in Huh7, HepG2 and Mahlavu cell 
lines (40x): The arrows show examples of cells that we consider as having nuclear DUSP10.
It is seen that DUSP10 localization changed due to the inhibitor in Huh7 and HepG2 
cell lines. DUSP10 amount also seemed to increase in inhibitor treated samples (IC50 
concentration), although we could not detect this increase with Western blotting.
Next, quantification of nuclear DUSP10 staining was done by taking the percentages 
of cells similar to the ones marked with arrows in the figures in total number of cells.
For this purpose, JNK inhibitor V treatment followed by DUSP10 immunostaining in 
Huh7, HepG2, Hep3B, Snu182 and Mahlavu cell lines were repeated twice more, 
completing the procedure to a triplicate. Three areas from each sample or control were 
counted, adding up to nine areas for each condition (0μM / 2μM / 4μM) considering a 
single cell line. The averages (and the standard deviations) are graphed in Fig.4.1.28a-
e, and significant changes are marked.
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Fig.4.1.28a: Change in nuclear DUSP10 localization percentage in Huh7 cell line due to JNK 
inhibitor V: ** means p < 0.001.
Fig.4.1.28b: Change in nuclear DUSP10 localization percentage in HepG2 cell line due to JNK 
inhibitor V: ** means p < 0.001.
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Fig.4.1.28c: Change in nuclear DUSP10 localization percentage in Hep3B cell line due to JNK 
inhibitor V: ** means p < 0.001.
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Fig.4.1.28d: Change in nuclear DUSP10 localization percentage in Snu182 cell line due to JNK 
inhibitor V: No significant change is observed.
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Fig.4.1.28e: Change in nuclear DUSP10 localization percentage in Mahlavu cell line due to JNK 
inhibitor V: No significant change is observed.
These results show that DUSP10 localization changes significantly in Huh7, Hep3B 
and HepG2 cell lines, which are well-differentiated HCC cell lines (see section 
4.1.4.1). Hence this difference in response to JNK inhibitor V may indicate a 
difference in the regulation of JNK pathway in well- versus poorly-differentiated cell 
lines.
In the website of Calbiochem, where JNK inhibitor V was bought from, it is stated
that for concentrations of JNK inhibitor V below 10μM, no inhibition of kinases other 
than JNK1/2/3 are seen. Although the growth-inhibitory concentration of JNK 
inhibitor V is known from yet unpublished results of our group, the inhibition of JNK 
due to this inhibitor was not yet confirmed. So our next move was to verify that the 
concentration of JNK inhibitor V we used efficiently inhibits JNK pathway. For this, 
Huh7 cells were incubated with or without 4μM JNK inhibitor V for 2 hrs. 
Afterwards, cells were additionally incubated with or without 300μM H2O2 for 2 hrs. 
Cell pellets were collected and after protein extraction, Western blotting was done to 
check for c-Jun transcription factor phosphorylation, which is the best known JNK 
target (hence the name; “c-Jun N-terminal kinase”). Fig.4.1.29 shows that JNK is 
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indeed inhibited by JNK inhibitor V in our experiments.
Fig.4.1.29: Effect of the used concentration of JNK inhibitor V on c-Jun phosphorylation in Huh7 
cells: The effective concentration and incubation time for H2O2 treatment of Huh7 cells is taken from 
Taki K et al, 2008. Total c-Jun blotting was done to check equal protein amounts. 
Since we observed a difference in DUSP10 localization between well- and poorly-
differentiated HCC cell lines in response to JNK inhibitor V, we wanted to see if 
amounts of active JNK or p38 also differ between these cell line types, somehow 
rendering the poorly-differentiated cells unresponsive to the inhibitor. The results are 
shown below.
Fig.4.1.30: Phosphorylated and total JNK or p38 amounts in HepG2, Hep3B, Snu182 and 
Mahlavu cell lines: Both JNK1 (46 kDA) and JNK2/3 (54 kDA) are recognized by these antibodies 
and result in two bands on the membrane. Only p38α is recognized by these antibodies. Tubulin is used 
as an internal control to check for equal protein loading.
It is seen that in poorly-differentiated cell lines, but not in well-differentiated ones, 
JNK and p38 are phosphorylated, which probably results in constitutive activity of 
these MAPKs that are related to a variety of responses including apoptosis and 
senescence.
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Additional experiments on this topic focused on confocal microscopy which we 
expected to give more detailed results on the change of DUSP10 localization in 
response to JNK inhibitor V. The results are shown below.
Fig.4.1.31: Confocal microscopy results on inhibitor treatment of selected HCC cell lines (40x):
All images were taken at the planes where DUSP10 staining is the highest. Interestingly, DUSP10 
shows high peri-nuclear staining in Snu182 cell line. Arrows are used to point out the cells that show 
nuclear DUSP10 staining in cell lines that normally have cytoplasmic DUSP10. Since JNK inhibitor V 
is a growth-inhibitory agent, the number of Hep3B and Hep3B-TR cells are observed to be decreased 
in response to treatment.
These results also confirm a shift from cytoplasm to nucleus for DUSP10, much better 
observed in well-differentiated cell lines (Hep3B and Hep3B-TR).
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An increase in DUSP10 staining intensity is also observed, especially according to 
Figs.4.1.27 (results for HepG2) and 4.1.31 (results for Hep3B and Hep3B-TR). We 
tried to quantify this increase in staining intensity by Western blotting against 
DUSP10. However, we could not observe an increase in DUSP10 protein amount, as 
shown below:
Fig.4.1.32: DUSP10 protein amounts upon JNK inhibitor V treatment in the cell lines employed:
No change in DUSP10 amount could be detected. Tubulin is used as an internal control to check for 
equal protein loading.
Hence all of these experiments have shown that DUSP10 changes its localization 
upon inhibition of JNK signaling in epithelial-like HCC cell lines. Inhibition of p38 
signaling does not affect DUSP10 localization. Additionally, localization change is 
not observed in mesenchymal-like HCC cell lines.
4.1.6 Ectopic overexpression studies for DUSP10
Expression vectors containing the coding sequence of DUSP10 isoform a, pEGFP-
DUSP10 and pcDNA-DUSP10, were constructed, as mentioned in Methods chapter. 
Transient transfection of these constructs were performed in Huh7 cell line. However 
no significant overexpression was detected after 48 hours of transfection (Fig.4.1.33).
These results may be pointing out a tight control over DUSP10 expression in Huh7.
      
Fig.4.1.33: No significant overexpression of DUSP10 is seen upon transient transfection: Huh7 
cells were transfected with empty and DUSP10-containing vectors. Proteins were were extracted 48 
hours later and Western blotting was done. Left, transient transfection results of pEGFP-DUSP10 are 
seen. The empty vector is pEGFP-N2 in this case. Right, transient transfection results of pcDNA-
DUSP10 are seen. The empty vector is pcDNA3.1/myc-His B.
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4.2 MTMR11
4.2.1 Bioinformatics analysis of MTMR11
4.2.1.1 Sequence and gene information
MTMR11 stands for “myotubularin related protein 11.” The NCBI Gene ID for 
MTMR11 is 10903. The locus in which MTMR11 gene resides is named as 
NC_000001 (version 10) and it corresponds to a 249250621 bp linear DNA sequence. 
It has been mapped to the minus strand of the q arm of human chromosome 1; its 
exact location is 1q12-21 according NCBI database and UCSC Human genome 
browser (Fig.4.2.1) (1q21.2 according to Ensembl database). Studies report gain of 1q 
in most of HCC samples analyzed, which implicates that the genes located on this 
chromosomal arm may be important in early stages of hepatocarcinogenesis (Tornillo 
L et al, 2002; Kitay-Cohen Y et al, 2001; Guan X-Y et al, 2000).
chromosome: 1; Location: 1q12-q21
Fig.4.2.1: Genomic context of MTMR11 gene.
The gene has two transcripts, coding for two protein isoforms a and b, a being the 
dominant one. Transcript variant 1 of 2879 nucleotides (NM_001145862.1) codes for 
isoform a of 709 aminoacids (NP_001139334.1) and has 17 exons. Transcript variant 
2 of 2368 nucleotides (NM_181873.3) codes for isoform b of 640 aminoacids 
(NP_870988.2) and also has 17 exons. The exons that MTMR11 transcript variant 1 
contain are named as 1, 2b, 3a, 4-16, 17b, whereas the exons that MTMR11 transcript 
variant 2 contain are named as 2a, 3b, 4-16, 17a and 17c. The translated region of 
transcript variant 1 is 2130 basepairs (bp) long whereas translated region of transcript 
variant 2 is 1923 bp long.
Additionally, 29 SNPs (single nucleotide polymorphisms) have been reported in 
GeneCards database (Rebhan M et al, Trends in Genetics, 1997) so far for MTMR11 
gene. Most SNPs are intronic. There are two non-synonymous SNPs located in this 
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gene. One of them is a M (methionine) to V (valine) aminoacid change at position 159 
of MTMR11 isoform a (position 87 of isoform b) with minor allele frequency of 0.22. 
The other is a Q (glutamine) to P (proline) aminoacid change at position 531 of 
isoform a (position 459 of isoform b) with minor allele frequency of 0.03. These 
SNPs are not associated with a disease state.
4.2.1.2 Protein information
4.2.1.2.1 General information
The protein encoded by MTMR11 gene is designated as “myotubularin related protein 
11.” MTMR11 isoform a is represented in SWISS-PROT Database by A4FU01-1 
symbol and it consists of 709 aminoacids, corresponding to a molecular weight of 
79.5 kDa and a theoretical isoelectric point (pI) of 6.59. MTMR11 isoform b is 
represented by A4FU01-4 symbol and it consists of 640 aminoacids, corresponding to 
a molecular weight of 72.1 kDa and a theoretical pI of 6.98. The presence of the other 
isoforms listed in SWISS-PROT Database are not supported by experimental 
evidence, and hence are included in this section.
MTMR11 isoform b lacks residues 1-72 of isoform a. Other differences are TNF 
(isoform a) to MPP (isoform b) change at position 73-75 of isoform a; and 
RAEGDLG (isoform a) to QSHPFWITRC (isoform b) change at position 703-709 of 
isoform a. MTMR11 belongs to a subfamily of phosphatases named as myotubularin 
phosphatases which are dual specificity phosphatases that can dephosphorylate both 
proteins and lipids (phosphoinositides).
4.2.1.2.2 Protein domains and motifs
MTMR11 is known to be a myotubularin related protein and thus contains such a 
domain according to Motif Scan search (Fig.4.2.2a and b). There are also different 
sites that may be subject to modification associated with each different isoform. These 
“possible” sites given by Motif Scan search are weak matches as they are motifs that 
are frequently found in other proteins and may not be specific to MTMR11.
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According to Gene Ontology (GO) Project, the molecular function terms associated 
with MTMR11 are DNA binding, ligand-dependent nuclear receptor activity and 
phosphatase activity. As seen in Fig.4.2.2a and b, MTMR11 has possible DNA 
binding domains and bipartite nuclear localization signals, hence these may be true 
sites. However SWISS-PROT lists MTMR11 as a probable pseudophosphatase since 
it contains a Glu residue instead of a conserved Cys residue in the catalytic loop 
rendering it catalytically inactive, although this information is not confirmed with 
experiments yet. In myotubularin related protein superfamily, there are a number of 
pseudophosphatases, which are thought to bind and regulate the active phosphatases. 
For example, pseudophosphatases MTMR5 and MTMR13 are known to be regulatory 
partners of MTMR2 (Kim S-A et al, 2003; Robinson FL, Dixon JE, 2005). Hence 
being a pseudophosphatase should not deprive MTMR11 of its value.
4.2.1.2.3 Protein structure
Secondary-structure information on MTMR11 isoforms was obtained by querying at 
NPS (Network Protein Sequence Analysis) database (Combet C et al, 2000),  using 
PHD (Rost B, Sander C, 1994), DSC (King RD, Stenberg MJ, 1996) and MLRC on 
GOR4, SIMPA96 and SOPMA (Guermeur Y et al, 1999) prediction methods. 
According to this, MTMR11 isoform a contains 26.09% alpha helices, 13.54% 
extended strands and 58.11% random coils (Fig.4.2.3a), and, MTMR11 isoform b 
contains 27.81% alpha helices, 13.28% extended strands and 56.56% random coils 
(Fig.4.2.3b).
Fig.4.2.3a: NPS consensus secondary structure prediction for MTMR11 isoform a: Red parts mark 
the extended strands, blue parts mark the alpha helices, and purple parts mark the random coils. Alpha 
helices are associated with the functional domain mostly.
Fig.4.2.3b: NPS consensus secondary structure prediction for MTMR11 isoform b: Red parts mark 
the extended strands, blue parts mark the alpha helices, and purple parts mark the random coils. Alpha 
helices are associated with the functional domain mostly.
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No three dimensional structure can be found for MTMR11 in PDB or ModBase 
databases.
4.2.1.3 Gene homologs and protein sequence conservation
4.2.1.3.1 Orthologs of MTMR11
According to HomoloGene Database of NCBI, orthologs of MTMR11 exist in five 
other species. This database only gives results for isoform b. These species, and the 
extent of identity between their MTMR11 genes/proteins and Homo sapiens
MTMR11 gene/protein is listed in Table 4.2.1.
Table 4.2.1: Orthologs of human MTMR11 and multiple alignment pair-wise similarity scores 
between MTMR11 protein and DNA sequences of different species.
The multiple sequence alignment of the protein sequences of these orthologs were 
generated using ClustalW2 (Thompson JD et al, 1997). Fig.4.2.4 shows the conserved 
residues among different species. The sequences aligned from top to bottom belong to 
Homo sapiens (human), Pan troglodytes (chimpanzee), Bos taurus (cow), Canis lupus 
familiaris (dog), Mus musculus (mouse) and Rattus Norvegicus (rat), respectively.
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Fig.4.2.4: ClustalW2 multiple sequence alignment of MTMR11 (transcript variant 2) orthologs: 
From top to bottom: Human, chimpanzee, cow, dog, mouse and rat orthologs are listed. Interestingly 
when the beginning 72 bases of dog, mouse and rat MTMR11 orthologs are compared to the first 72 
bases of MTMR11 transcript variant 1, a very high similarity is seen. The results continue in the 
following pages.
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Fig.4.2.4 (continued): ClustalW2 multiple sequence alignment of MTMR11 (transcript variant 2) 
orthologs: From top to bottom: Human, chimpanzee, cow, dog, mouse and rat orthologs are listed. 
Interestingly when the beginning 72 bases of dog, mouse and rat MTMR11 orthologs are compared to 
the first 72 bases of MTMR11 transcript variant 1, a very high similarity is seen. The results continue 
in the next page.
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Fig.4.2.4 (continued): ClustalW2 multiple sequence alignment of MTMR11 (transcript variant 2) 
orthologs: From top to bottom: Human, chimpanzee, cow, dog, mouse and rat orthologs are listed. 
Interestingly when the beginning 72 bases of dog, mouse and rat MTMR11 orthologs are compared to 
the first 72 bases of MTMR11 transcript variant 1, a very high similarity is seen.
4.2.1.3.2 Paralogs of MTMR11
MTMR11 belongs to a phosphatase subfamily named as myotubularin phosphatases 
under the family dual specificity phosphatases, as already mentioned. A phylogenetic 
showing the relations of myotubularin phosphatases are shown in Fig.4.2.5. 
Additionally, conserved motifs found in all MTMRs are shown in Fig.4.2.6.
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Fig.4.2.5: Phylogenetic tree of myotubularin phosphatase gene family with branch lengths: 
Includes only human genes. Paralogs are gathered by KEGG SSDB paralog search. Phylogenetic tree is 
generated by MAFFT sequence alignment.
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Fig.4.2.6: Conserved motifs in myotubularin phosphatases: DENN stands for “differentially 
expressed in neoplastic versus normal cells,” and have yet to be experimentally characterized, but are 
proposed to function as GTPase effector domains. PH-GRAM (GRAM stands for 
“glucosyltransferases, Rab-like GTPase activators and myotubularins,” the proteins it was first found 
in) domains are important in protein- or lipid-binding interactions. PH domains (stands for “pleckstrin 
homology”) are best known as phosphoinositide-binding modules that target their host proteins to 
specific cell membranes. FYVE domain (stands for “FYVE finger-containing phosphoinositide kinase 
(Fab1), vesicle transport protein Vac 1, and EEA1,” the proteins it was first found in) is a PIP-binding 
module known to target host proteins to endosomal membranes where PIP (inositol monophosphate) is 
concentrated. Coiled-coil motifs are predicted in most myotubularins and, in several cases, mediate 
interactions between active and inactive family members. PDZ-binding motif (stands for “postsynaptic 
density 95, disk large, zona occludens-1,” the proteins it was first found in) is a small protein-protein 
interaction module that is thought to play a role in the clustering of submembranous signalling 
molecules. Myotubularin phosphatase domain is a type of PTP domain that is larger and contains 
regulatory domains. The figure is taken from Begley MJ, Dixon JE, 2005. 
4.2.1.4 MTMR11 in gene expression profiling arrays
MTMR11 was searched for in Oncomine Cancer Profiling Database. Once found, 
differential expression data in liver tissue were searched for. The results are plotted in 
Fig.4.2.7a and b. MTMR11 gave significant results in both of the two important 
studies on liver (Wurmbach_Liver and Chen_Liver). Interestingly, this gene shows an 
upregulation in HCC compared to non-tumorous tissues. This may point out to the 
fact that MTMR11’s upregulation in senescent clones according to our group’s 
microarray data is coincidental, and it is not functionally related to the reversion of 
immortal phenotype seen in these clones.
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Fig.4.2.7a: MTMR11 expression in Wurmbach microarray data: Normal (Class 1, n=10) vs HCC 
(Class 2, n=35), p=1.5E-4.
Fig.4.2.7b: MTMR11 expression in Chen microarray data: Non-tumor liver (Class 1, n=76) vs 
HCC (Class 2, n=104), p=0.003.
Additionally, in both microarray data, the non-tumorous expression of MTMR11 
occurs in a more compact range, which means that it is expressed in similar levels in 
all normal samples, whereas its cancerous expression occurs in a larger range, 
meaning there is considerable difference in expression of this gene in different HCC 
samples. The grades and prognostic information of the HCC samples used could still 
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indicate an importance of this gene in HCC.
4.2.1.5 Expression data
On the UCSC (University of California, Santa Cruz) Genome Browser website, the 
expression data of MTMR11 isoform a can be obtained from several microarray 
studies. The data gathered from the GNF Expression Atlas 2 human data on Affy 
U133A and GNF1H chips (Su AI et al, 2002), where red represents high expression 
level and green represents low expression level, is shown in Fig.4.2.8.
Fig.4.2.8: Expression data of DUSP10 based on the GNF Expression Atlas 2 Data from U133A 
and GNF1H Chips.
According to this expression data, although generally all tissues and cells tested 
expressed MTMR11 to a certain level (as indicated by the dominance of the black 
color), it is expressed more in some differentiated immune system and hematopoietic 
105
lineage cell types, adrenal gland and adrenal cortex. Relatively low levels of 
MTMR11 is detected in remaining differentiated immune system and hematopoietic 
lineage cell types, promyelocytic leukemia, chronic myelogenous leukemia and fetal 
liver.
4.2.2 Analysis of MTMR11 expression change between senescent and immortal 
Huh7 clones
Just like DUSP10 case, as a first step, we performed PCR to verify MTMR11
differential expression in C1, C3-Early and C3-Late clones. The result of this PCR 
and a graph to show the relative expression of MTMR11 in each clone are shown 
below:
Fig.4.2.9a: MTMR11 is upregulated in senescent and revertant clones compared to the immortal 
clone: cDNA from C1 (immortal clone), C3-Early (revertant clone) and C3-Late (senescent clone) 
were used for semi-quantitative RT-PCR experiments. GAPDH: Glyceraldehyde-3-phosphate 
dehydrogenase was used as an internal control. (-): Negative control well to check for nucleic acid 
contaminants.
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Fig.4.2.9b: MTMR11 is upregulated in senescent and revertant clones compared to the immortal 
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clone: A graph was generated by normalization of MTMR11 band intensities according to GAPDH 
band intensities in Fig.4.14a. Intensities were quantified by Bio-1D program.
The results shown in Fig.4.2.9a and b indicate that DUSP10 expression is increased 
progressively from C1 immortal clone to C3 senescent clone. There is a deviation 
from the fold changes observed in the original microarray data (2.1 fold increase in 
revertant vs immortal clone and 3.0 fold increase in senescent vs immortal clone). 
This may be due to the method of band intensity measurement or due to the 
insensitivity of the semi-quantitative PCR. Still, it is clearly seen that MTMR11 is 
upregulated in senescent cells in contrast to immortal ones.
4.2.3 MTMR11 expression data
We proceeded by gathering DUSP10 mRNA expression data in HCC cell lines 
(Fig.4.2.10). For this purpose, cDNAs from various HCC cell lines were extracted and 
used in semi-quantitative PCR.
Fig.4.2.10: MTMR11 mRNA levels in HCC cell lines: Huh7, Hep40, HepG2, Hep3B, Hep3B-TR, 
PLC are classified as well-differentiated cell lines. Snu182, Snu387, Snu398, Snu423, Snu449, Snu475, 
SK Hep1, Mahlavu and Focus are classified as poorly differentiated cell lines. GAPDH was used as an 
internal control. (-) well showed no contamination.
4.2.4 MTMR11 transcript variants in different cell lines
Fig.4.2.11: RT-PCR primer pairs for MTMR11 used in our studies and the lengths of the PCR 
products produced: MTMR11 intron spanning primer pair was employed to differentiate between the 
MTMR11 intron 
spanning primers
900 bp: Possible 
genomic DNA 
contamination due to 
experimental errors
600 bp: The new 
transcript (t.v. 1)
340 bp: The original 
transcript (t.v. 2)
Total MTMR11 
primers
160 bp: All 
MTMR11 
transcripts
          Huh7     Hep     Hep     Hep      Hep     PLC     Snu     Snu      Snu     Snu      Snu     Snu      SK    Mahlavu Focus    (-)
                            40      G2        3B     3B-TR                182      387      398      423       449     475     Hep1
MTMR11
GAPDH
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transcript variants.
MTMR11 transcript variant 1 is a very recently discovered form of MTMR11. Before 
March 2009, the only MTMR11 transcript that could be found in databases was 
MTMR11 transcript variant 2, as it is now called. Roughly the same time, we 
observed the highly dominant MTMR11 transcript variant in HCC cell lines 
(MTMR11 transcript variant 1) while working to clone MTMR11. According to 
sequencing results (done at İONTEK), this variant seemed to retain the last intron 
(now listed as a part of exon 17b), resulting in RAEGDLG to QSHPFWITRC change 
in the C-terminus of the protein. Also this variant had extra 216 bases in 5’-end of the 
coding sequence, resulting in extra 72 residues in the N-terminus of the protein. We 
were immediately interested in scanning for the two different variants in HCC and 
breast cancer cell lines, in addition to C1, C3-Early and C3-Late clones. We designed 
our primers so that the pair would span the last two introns (the last intron is known as 
a part of exon 17b now, as already mentioned), hence both the new transcript 
(transcript variant 1), the original transcript (transcript variant 2) and amplification 
due to possible genomic DNA contamination would be detected. RT-PCR primers for 
MTMR11 are depicted in Fig.4.2.11.
4.2.4.1 MTMR11 transcript variants in senescent and immortal clones
We continued by checking if one or both transcript variants of MTMR11 are 
upregulated in senescent clones compared to immortal ones.
Fig.4.2.12: MTMR11 transcript variants in the established clones: cDNA from C1 (immortal 
clone), C3-Early (revertant clone), C3-Late (senescent clone), G11 (immortal), G12-Late (senescent)
were used for this semi-quantitative RT-PCR experiment. GAPDH: Glyceraldehyde-3-phosphate 
dehydrogenase was used as an internal control. (-): Negative control well to check for nucleic acid 
contaminants.
In Fig.4.2.12, it is seen that both forms of MTMR11 are upregulated in C-clones, 
                 C1       C3E      C3L         (-)
MTMR11
GAPDH
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whereas only transcript variant 1 is detectable in the senescent G12-Late clone. 
Interestingly, the above bands are also much higher in intensity in the senescent C3-
Late clone compared to revertant and immortal clones. Although a 900-bp band can 
be the result of genomic DNA amplification, it should also have shown up in 
immortal and revertant clones, hence the above bands might potentially belong to 
other transcript variants.
4.2.4.2 MTMR11 transcript variants in HCC cell lines
MTMR11 transcript variants in HCC cell lines were also checked. The results are 
shown below.
Fig.4.2.13: MTMR11 transcript variants in HCC cell lines: Some cell lines (such as PLC and 
Snu475) seem to have five bands instead of three, which may indicate that there are additional 
transcript variants of MTMR11 considering this region. Green marks the well-differentiated cell lines 
and dark purple marks the poorly-differentiated cell lines.
Essentially all HCC cell lines contain both transcript variants. These results also 
indicate the possibility of other transcript variants in this region.
4.2.4.3 MTMR11 transcript variants in breast cancer cell lines
MTMR11 transcript variants in breast cancer cell lines were also amplified. The 
results of a saturated RT-PCR (40 cycles of amplification) are shown in Fig.4.2.14. 
CAMAI and MDA MB-453 cell lines lack transcript variant 2. These results also 
strengthen the possibility that other transcript variants of MTMR11 might be present.
Fig.4.2.14: MTMR11 transcript variants in breast cancer cell lines: CAMAI and MDA MB-453 
seem to be deficient in the shorter transcript. T47D has five bands instead of three, which may indicate 
    Huh7     Hep     Hep      Hep     Hep     PLC    Snu       Snu     Snu     Snu       Snu     Snu     SK   Mahlavu Focus     (-)
                   40        G2        3B    3B-TR                182      387       398      423       449      475     Hep1
MTMR11
GAPDH
  BT20      HCC 1937    MCF-7       BT474       CAMA I        T47D    MDA MB-453 MDA MB-231
MTMR11
GAPDH
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that there are additional transcript variants of MTMR11 considering this region. Dark blue marks the 
basal-originated cell lines, blue/green marks the luminal-originated cell lines and dark pink marks the 
mesenchymal-originated cell line.
4.2.5 Sequencing of the extra bands in RT-PCR experiments
Finally, we isolated the bands resulting in MTMR11 PCR, after an amplification 
reaction in T47D cells. We could isolate and send 340bp, 600bp, 800bp and 900bp 
bands for sequencing. The results for 340bp, 600bp and 900bp bands were as 
expected; 340bp represented MTMR11 transcript variant 2, 600bp represented 
MTMR11 transcript variant 1 and 900bp represented the DNA sequence bearing both 
introns within. Interestingly 800bp band has a 200bp insertion after the forward 
primer sequence, but other than that, it has the same sequence as 600bp band. 
However the inserted sequence came out to be simply a repeat of reverse and forward 
primers, which may mean that Taq DNA polymerase has erroneously amplified this 
region. The results of sequencing can be viewed below:
Fig.4.2.15a: 340bp band sequencing results: Above, the color key for alignment scores and the 
representative alignment of the query sequence with the resulted sequences can be viewed. For all 
sequencing results, there were three results, listed from top to bottom: Homo sapiens myotubularin 
related protein 11 (MTMR11) - mRNA, Homo sapiens chromosome 1 genomic contig - reference 
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assembly, Homo sapiens chromosome 1 genomic contig - alternate assembly (based on HuRef 
SCAF_1103279188338). Below, the alignment of 340bp band query with MTMR11 mRNA. The extra 
sequences that did not give an alignment with any human DNA or mRNA sequence come from the 
pGEMT-Easy vector which was used to clone the isolated bands.
Fig.4.2.15b: 600bp band sequencing results: Above, the color key for alignment scores and the 
representative alignment of the query sequence with the resulted sequences can be viewed. For all 
sequencing results, there were three results, listed from top to bottom: Homo sapiens myotubularin 
related protein 11 (MTMR11) - mRNA, Homo sapiens chromosome 1 genomic contig - reference 
assembly, Homo sapiens chromosome 1 genomic contig - alternate assembly (based on HuRef 
SCAF_1103279188338). Below, the alignment of 600bp band query with human chromosome 1 
genomic contig (reference assembly). An intron is retained in this sequence compared to the 340bp 
band. The extra sequences that did not give an alignment with any human DNA or mRNA sequence 
come from the pGEMT-Easy vector which was used to clone the isolated bands.
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Fig.4.2.15c: 800bp band sequencing results: Above, the color key for alignment scores and the 
representative alignment of the query sequence with the resulted sequences can be viewed. For all 
sequencing results, there were three results, listed from top to bottom: Homo sapiens myotubularin 
related protein 11 (MTMR11) - mRNA, Homo sapiens chromosome 1 genomic contig - reference 
assembly, Homo sapiens chromosome 1 genomic contig - alternate assembly (based on HuRef 
SCAF_1103279188338). Below, the alignment of 800bp band query with human chromosome 1 
genomic contig (reference assembly). After a thorough analysis of this sequence, it was understood that 
a 200bp sequence of primer repeats were inserted. Other than that, the sequence is the same as the 
600bp sequence. The extra sequences that did not give an alignment with any human DNA or mRNA 
sequence come from the pGEMT-Easy vector which was used to clone the isolated bands.
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Fig.4.2.15d: 900bp band sequencing results: Above, the color key for alignment scores and the 
representative alignment of the query sequence with the resulted sequences can be viewed. For all 
sequencing results, there were three results, listed from top to bottom: Homo sapiens myotubularin 
related protein 11 (MTMR11) - mRNA, Homo sapiens chromosome 1 genomic contig - reference 
assembly, Homo sapiens chromosome 1 genomic contig - alternate assembly (based on HuRef 
SCAF_1103279188338). Below, the alignment of 900bp band query with human chromosome 1 
genomic contig (reference assembly). This sequence was expected to be amplified from possible 
genomic DNA contaminants. As expected, it has the whole sequence from genomic DNA, with both 
introns spanned. The extra sequences that did not give an alignment with any human DNA or mRNA 
sequence come from the pGEMT-Easy vector which was used to clone the isolated bands.
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CHAPTER 5. DISCUSSION
In this study, we focused on the novel protein phosphatase genes DUSP10 and 
MTMR11 in HCC. Our starting point for choosing these genes was the result of a 
microarray study that was performed by our group (Öztürk M et al, unpublished data) 
for identifying the gene expression changes between the senescent and the immortal 
Huh7 clones established previously (Öztürk N et al, 2006). In the significant gene list 
of protein phosphatases representing the most differentially expressed phosphatases 
between these stable clones, DUSP10 and MTMR11 appeared as the genes that were 
significantly upregulated in the senescent clones with respect to the immortal clones. 
Therefore, we decided to analyze DUSP10 and MTMR11 genes.
After a thorough bioinformatics search, we generated the expression data of DUSP10 
and MTMR11 in the immortal and senescent clones. RT-PCR results showed that both 
DUSP10 and MTMR11 were upregulated in senescent clones as compared to 
immortal clones which is in correlation with the microarray study. We continued by 
constituting  DUSP10 and MTMR11 expression data in HCC and breast cancer cell 
lines. It was concluded that expression of both genes (and DUSP10 protein) was 
present in essentially all the cell lines we employed.
Initially we focused our attention on DUSP10. Since the expression data in HCC cell 
lines did not demonstrate a difference between mesenchymal-like and epithelial-like 
cell lines, we wanted to see if subcellular localization of DUSP10 might be important 
in differentiating between the two types of cell lines. We checked the subcellular 
localization of DUSP10 by immunoperoxidase staining and immunofluorescence. 
This protein is listed as having a unique distribution in SWISS-PROT Database, as it 
is said to be seen evenly in both nucleus and cytoplasm. However we observed that
while in some cell lines DUSP10 is seen both in nucleus and cytoplasm roughly in 
similar intensities (Huh7, Hep40, Hep3B-TR, PLC, Focus, SK-Hep1), some cell lines 
showed strong nuclear DUSP10 (HepG2, Snu182 and Snu398) and some showed 
predominantly cytoplasmic DUSP10 (Hep3B, Snu387, Snu423, Snu449, Snu475 and 
Mahlavu). The cytoplasmic DUSP10 seemed to concentrate immediately around 
nuclei in most cell lines that gave cytoplasmic DUSP10 staining and into cytoplasmic 
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foci in the rest (Snu449 and SK-Hep1).
We did not observe a colocalization between DUSP10 and Calnexin proteins after 
confocal microscopy, although the peri-nuclear DUSP10 staining observed in most of 
the cell lines hinted at its localization to ER. In contrast, we observed that DUSP10 
localizes in the cytoplasm. While we could not state that DUSP10 specifically 
localizes to the ER, its peri-nuclear distribution was still of interest to us as it might 
have something to do with translocation of DUSP10 to nucleus when needed. It is 
known that MKPs translocate to nucleus to deactivate MAPKs within the nucleus 
(Patterson KI et al, 2009). 
The observation that predominantly nuclear DUSP10 localization is seen in some cell 
lines and predominantly cytoplasmic localization in the others drew our attention to 
the factors that may be changing DUSP10 localization. We tried to correlate a change 
of DUSP10 localization with induction of senescence. We saw a difference in 
DUSP10 localization upon comparison of early and late passages of MRC-5 
fibroblasts demonstrating that DUSP10 may be translocating to nucleus during 
replicative senescence. We saw no change in DUSP10 localization was seen upon 
treatment of Huh7 cells with the senescence-inducing agents, TGF-β and 
camptothecin, indicating that DUSP10 localization is not changed during premature 
senescence. Hence although we could not conclude that DUSP10 localization changes 
upon induction of premature senescence, we can conclude that it changes upon 
induction of replicative senescence. If the change in DUSP10 localization indicates an 
important regulatory mechanism, this finding strengthens the microarray study done 
previously, from which DUSP10 emerged as a replicative senescence-associated 
phosphatase gene (Öztürk M, unpublished data).
We further reasoned that disruption of JNK and p38 MAPK pathways may affect 
DUSP10 localization, and used inhibitors of these kinases on selected cell lines. The 
inhibitors we used were ATP-competitive, preventing their targets to activate 
downstream elements regardless of their phosphorylation statuses. We chose to work 
with Huh7, HepG2, Hep3B, Hep3B-TR, Snu182 and Mahlavu cell lines in inhibitor 
experiments for a number of reasons. The stable clones that form the basis of this 
research have been established from Huh7 cell line (Öztürk N et al, 2006).
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Additionally, the proliferation-inhibitory concentrations of JNK inhibitor V used were 
measured in Huh7 cell line (Bilget-Güven E et al, unpublished data). We employed 
HepG2 and Hep3B cell lines as these were well-differentiated cell lines that showed 
nuclear or cytoplasmic DUSP10 staining, respectively. We employed Snu182 and 
Mahlavu cell lines for a similar reason, since these were poorly-differentiated cell 
lines that showed nuclear or cytoplasmic DUSP10 staining, respectively. We also 
employed Hep3B-TR (TGFβ-Resistant) cell line in the final confocal microscopy 
experiment, to see if absence of TGFβ receptors I and II causes a difference in the 
response of cells to JNK inhibitor V, since one of the upstream elements of this 
pathway is TGFβ-activated kinase 1 (TAK1 or MAP3K7) (Hammaker DR et al, 
2007).
Upon inhibitor experiments on Hep3B cell line, we saw that JNK inhibitor V caused 
translocation of DUSP10 from cytoplasm to nucleus. We treated Snu182 cell line with 
JNK inhibitor V and p38 inhibitors, too, however did not observe a change in 
DUSP10 localization. JNK inhibitor V treatment study was expanded to Huh7, 
HepG2, Snu182 and Mahlavu cell lines, resulting in significant DUSP10 translocation 
in well-differentiated (epithelial-like) cell lines (Huh7, HepG2, Hep3B), but no 
significant translocation in poorly-differentiated (mesenchymal-like) cell lines 
(Snu182, Mahlavu). We also quantified the significance of this translocation, and 
verified that JNK pathway is inhibited by the used concentration of this inhibitor. 
Finally we confirmed DUSP10 translocation upon JNK inhibitor V treatment in well-
differentiated cell lines, Hep3B and Hep3B-TR, by confocal microscopy compared to 
the poorly-differentiated cell lines Snu182 and Mahlavu. Effect of JNK inhibitor V on 
JNK is shown below.
Fig.5.1: Effect of JNK inhibitor V on JNK pathway: JNK inhibitor V competes with ATP to inhibit 
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phosphorylation of JNK targets by the kinase, regardless of the phosphorylation status of JNK.
Tumor suppressive or oncogenic activity of DUSP10 is not clear in HCC, although it 
is clear that the chromosomal region DUSP10 gene resides in is a hot spot for 
chromosomal aberrations in early HCC (see Results chapter, section 4.1.1.1). As 
mentioned in Introduction chapter, it functions as a tumor suppressor by deactivating 
the inflammatory MAPK p38 in early prostate cancer. Considering HCC, there is 
evidence that p38 MAPK may be functioning as a tumor suppressor. Studies with a 
constitutively active mutant of MKK6 and p38 inhibitors suggested that resistance of 
human HCC to apoptosis may be resulting due to a reduction in p38 activity (Iyoda K 
et al, 2003). Another study has shown that IL-6, a p38 target cytokine, mediates 
G0/G1 growth arrest in HCC cells through STAT3-dependent regulation of cdk2/cdk4 
activity and p21 expression (Moran DM et al, 2008). Additionally, p38α has been 
found to suppress normal hepatocyte and HCC proliferation by antagonizing the JNK-
c-Jun pathway, implicating p38α as a tumor suppressor and JNK as an oncogenic 
protein in HCC (Hui L et al, 2007). Further studies have supported the role of JNK in 
promoting proliferation in human HCC and chemically induced mouse liver cancers 
and shown that JNK1-dependent p21 downregulation is responsible for this effect 
(Hui L et al, 2008). Taking these into consideration, the role of DUSP10 which is able 
to deactivate both phosphatases, is not clear in HCC.
In this piece of work, we showed that JNKs affect DUSP10 subcellular localization 
but that p38s do not. This has significant importance since it is known that change in 
subcellular localization is a way of MKP/DSP regulation in cells, mainly through 
phosphorylation or myristoylation (Patterson KI et al, 2009). There are also examples 
of known tumor suppressor or oncogenic proteins which are regulated through 
subcellular localization and sequestration in specific locations, such as p33ING1b, β-
catenin and p53 (Sayan B et al, 2009; Farazi PA, DePinho RA, 2006). Our findings 
and this information sums up to the possibility that DUSP10 is regulated by JNKs
through a change in subcellular localization. Since it is known by large scale studies 
that DUSP10 isoform a may be phosphorylated in its N-terminus and that according 
to GPS 2.1 (kinase-specific phosphorylation site prediction), JNKs are among the 
kinases that may be phosphorylating the predicted residue on DUSP10, the change in 
subcellular localization may be occuring through this post-translational modification. 
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Additionally, N-myristoylation sites have been found on DUSP10 according to Motif 
Scan, however these may not be specific and experimental evidence is required. 
Furthermore, DUSP10 has an unusual proline-rich N-terminal sequence that is 
suspected to bear regulatory regions and non-canonical nuclear localization 
sequences. All of these strengthen the possibility that the change in DUSP10 
localization upon inhibition of JNKs is a significant finding that hints at a mechanism 
of DUSP10 regulation in HCC cells. The finding that DUSP10 may primarily be 
regulated by JNK in HCC cell lines also implicates that DUSP10 may be acting as a 
tumor suppressor in HCC, since JNK has been found to act like an oncogenic protein 
in the study of Hui L et al (Hui L et al, 2007).
On MTMR11 part, after finding out that MTMR11 has two main transcript variants 
during cloning experiments, and seeing that a new transcript is listed in databases, we 
were interested in seeing if the expression of these transcript variants change in 
different cell lines. For HCC cell lines, we wondered if there was a difference between 
well- and poorly-differentiated cells. For breast cancer cell lines, we wondered if there 
was a difference between cell lines originating from different breast tissues (basal, 
mesenchymal or luminal regions). However a significant difference was not observed.
Additionally, the microarray studies of Wurmbach and Chen demonstrate MTMR11 
upregulation in HCC samples. This might be showing that MTMR11, which emerged 
as a senescence-associated gene, is not related to senescence functionally. Still, in the 
microarray results of Wurmbach and Chen, MTMR11’s expression seemed to vary 
between different HCC samples, hence knowledge of the grades and the prognosis of 
the HCC samples used could be of use in relating MTMR11 to hepatocarcinogenesis.
Other than this, we saw that other unknown transcripts may exist considering the 
region we explored (last two or three exons of MTMR11). One of the unexpected 
bands, observed as a 550bp band right under the dominant 600bp band, could not be 
isolated and sent for sequencing. The other unexpected band, observed as a 800bp 
band under the expected 900bp band, had a surprising sequence which was mainly the 
same as the 600bp band but had a 200bp insertion of reverse and forward primer 
repeats. This may render 800bp band as a Taq DNA polymerase error in the PCR 
conditions used (Methods, section 3.3.7, Table 3.2). Still, the presence of this band in 
almost all of the cell lines we employed is striking. Finally, 900bp band had the 
expected sequence of both introns spanned, resembling the sequence that would have 
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been amplified from genomic DNA. However, this does not completely show that this 
band has only resulted from genomic DNA amplification. RT-PCR results from HCC 
cell lines still hint at 900bp band as the sequence amplified from yet another novel 
transcript, since it is found in varying amounts in different cell lines explored 
(Fig.4.2.13).
In our study, we worked on DUSP10 and MTMR11 which code for protein 
phosphatases that we saw to be significantly upregulated in senescent stable clones of 
Huh7 compared to immortal ones. The gene expression profile changes between these 
different clones were of great interest, since exploration of genes with differential 
expression could be a key to reversion of the immortality of cancer cells. Since 
protein kinases are known to be very important in disease formation and 
carcinogenesis, their partners in signaling, protein phosphatases should also be 
important in these processes, although they have started to be appreciated only 
recently. Hence exploration of protein phosphatases and their genes with differential 
expression between immortal and senescent clones might provide a mechanism to 
overcome the immortality of cancer cells. Because overexpression studies could not 
be done in case of DUSP10 (probably due to the fact that its overexpression is 
immediately suppressed in cells) and were not done in MTMR11’s case (since we first 
wanted to focus on finding out if different transcript variants are seen in different cell 
lines), we could not assess whether protein products of these genes function in 
reversion of the immortal phenotype of Huh7 cell line or not. Still, we reached to 
important clues in analysis of these genes and their products. For MTMR11, we came 
to the conclusion that other transcript variants may be present in HCC and breast 
cancer cell lines, although no connection between MTMR11 and senescence or 
carcinogenesis is found yet. For DUSP10, we came to the conclusion that the change 
in DUSP10 subcellular localization may be associated with induction of replicative 
senescence and that JNKs may be regulating DUSP10 through its subcellular 
localization in well-differentiated HCC cell lines. Since JNK has also been found to 
function as an oncoprotein in HCC, this may be hinting at a tumor suppressive role for 
DUSP10 in hepatocarcinogenesis (Hui L et al, 2007). The significance of the change 
in DUSP10 localization should be characterized further, before stating that DUSP10 
functions in replicative senescence or hepatocarcinogenesis.
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CHAPTER 6. FUTURE PERSPECTIVES
Our results indicate DUSP10 and MTMR11 as senescence-upregulated phosphatase 
genes. Experiments that should be performed for confirmation of preliminary
DUSP10 data and for finding out a molecular mechanism for the regulation of 
DUSP10 localization change by JNK are summarized below:
- Confirmation of DUSP10 localization change in response to JNK inhibitor V by 
Western blotting of nuclear and cytoplasmic fractions of cells should be done by 
subcellular fractionation of the cell lines employed (Huh7, HepG2, Hep3B, Hep3B-
TR, Snu182 and Mahlavu), followed by DUSP10 Western blotting.
- Experiments with JNK inhibitor V should be performed in other HCC cell lines to 
verify the difference between well- and poorly-differentiated cell lines.
- Changes in DUSP10 localization should be checked upon JNK activation.
- DUSP10 localization may also be checked in cell lines that have differential JNK 
activities.
- Co-immunoprecipitation or co-staining experiments with DUSP10 / p38 and 
DUSP10 / JNK in HCC cell lines should be performed to see if DUSP10 prefers one 
of these targets in HCC cell lines. DUSP10 targeting JNKs in HCC would be useful in 
explaining why JNKs regulate DUSP10 subcellular localization.
- RNA interference experiments may be done against JNK, to check DUSP10 
localization when JNK expression is knocked-down. This does not necessarily give 
the same result with the inhibitor, since the inhibitor blocks JNK target 
phosphorylation and not the expression or activation of JNK itself.
- How DUSP10 translocates to nucleus is also an interesting question. JNK and p38 
MAPKs are known to translocate to nucleus upon phosphorylation. Co-
immunoprecipitation of DUSP10 with these MAPKs can be done after inhibitor 
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treatment in well-differentiated cell lines, or without inhibitor treatment in Snu182 
cell line since it naturally possesses nuclear DUSP10.
- Another future study may focus on the analysis of DUSP10 promoter sequence to 
find true AP-1 or ATF-2 sites, and afterwards, check if a transcriptional regulation is 
asserted on DUSP10 by p38 or JNK through ATF-2 in HCC cell lines.
- Construction of a DUSP10-containing expression vector with an inducible system
such as Tetracycline regulated systems, may prove to be useful in overexpression 
studies of DUSP10, if its ectopic overexpression is prevented by the cells.
Experiments that should be performed for confirmation of preliminary MTMR11 data
and for long term studies on this gene and its product are summarized below:
- MTMR11 transcript variants can be checked by RT-PCR in cDNAs from tumor vs 
non-tumor samples or aging vs young normal cell lines or premature senescence-
induced vs normal cell lines.
- Other transcript variants of MTMR11 can be searched for, since the cloning PCR for 
MTMR11 gives many bands (not shown).
- Yeast-2-hybrid studies for MTMR11 should be done to search for its possible 
myotubularin phosphatase partners.
- Antibodies should be produced against MTMR11.
- Since MTMR11 is predicted to bind to DNA and have ligand-dependent nuclear 
receptor activity, this can be confirmed by immunostaining to detect its localization, 
followed by ChIP to see which sequence it binds to, in normal and cancer cell lines.
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